var title_f22_3_22576="Normal ciliary structure";
var content_f22_3_22576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal ciliary structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross-sectioned axoneme from a man with normal, motile cilia and spermatozoa. Nine microtubular doublets form a circle, 0.2 micrometer wide, surrounding two central microtubules. Along each of the nine doublets there is a row of outer dynein arms and a row of inner dynein arms. These dynein arms are the force-producing elements in cilia and sperm flagella.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Afzelius, BA, Dallai, R, Lanzavecchia, S, Bellon, PL. Flagellar structure in normal human spermatozoa and in spermatozoa that lack dynein arms. Tissue Cell 1995 27:241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22576=[""].join("\n");
var outline_f22_3_22576=null;
var title_f22_3_22577="Extraocular muscles";
var content_f22_3_22577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Extraocular muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three pairs of extraocular muscles move each eye. The superior rectus and inferior oblique muscles primarily move the eye upward. The inferior rectus and superior oblique muscles primarily move the eye downward. The lateral rectus moves the eye horizontally laterally (abduction). The medial rectus muscle moves the eye horizontally medially (adduction). The superior oblique muscle incyclotorts the eye, and the inferior oblique muscle excyclotorts the eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22577=[""].join("\n");
var outline_f22_3_22577=null;
var title_f22_3_22578="Marfan syndrome dislocated lens";
var content_f22_3_22578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ectopia lentis (dislocated lens) in Marfan syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Slit-lamp photomicrography shows ectopia lentis with microspherophakia; the lens is completely luxated into the anterior chamber, predisposing to pupillary block glaucoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold DH, MD, and Weingeist TA, MD, PhD. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22578=[""].join("\n");
var outline_f22_3_22578=null;
var title_f22_3_22579="Crohns B mode US";
var content_f22_3_22579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    B-mode ultrasound image of a patient with ileocecal Crohn's disease showing bowel wall thickening of the cecum with transmural inflammatory reaction. Bowel wall thickening (6 mm) of the hypoechoic mucosa (M), echorich submucosa (SM) and echopoor muscularis propria (Musc) is indicated. The lumen is not seen due to mucosal swelling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christoph F Dietrich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22579=[""].join("\n");
var outline_f22_3_22579=null;
var title_f22_3_22580="Cetrorelix: Drug information";
var content_f22_3_22580=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetrorelix: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/15/37108?source=see_link\">",
"    see \"Cetrorelix: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cetrotide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cetrotide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F148972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin Releasing Hormone Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F148951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Controlled ovarian stimulation in conjunction with gonadotropins (FSH, hMG):",
"     </b>",
"     Female: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Single-dose regimen:",
"     </i>",
"     3 mg given when serum estradiol levels show appropriate stimulation response, usually stimulation day 7 (range: days 5-9). If hCG is not administered within 4 days, continue cetrorelix at 0.25 mg/day until hCG is administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Multiple-dose regimen:",
"     </i>",
"     0.25 mg morning or evening of stimulation day 5, or morning of stimulation day 6; continue until hCG is administered.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F148952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not intended for use in women &ge;65 years of age (Phase 2 and Phase 3 studies included women 19-40 years of age).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F148953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7676114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cetrotide&reg;: 0.25 mg, 3 mg [contains mannitol; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F148928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cetrorelix is administered by SubQ injection following proper aseptic technique procedures. Injections should be to the lower abdomen, preferably around the navel (but staying at least 1 inch from the navel). The injection site should be rotated daily. The needle should be inserted completely into the skin at a 45-degree angle.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F148927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F148970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Ovarian hyperstimulation syndrome, WHO grade II or III (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT, AST, GGT, and alkaline phosphatase increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylactic reactions (cough, hypotension, rash); local injection site reactions (bruising, erythema, itching, pruritus, redness, swelling)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F148931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cetrorelix or any component of the formulation; extrinsic peptide hormones, mannitol, gonadotropin releasing hormone (GnRH) or GnRH analogs; severe renal impairment; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F148915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Monitor carefully after first injection for possible hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergies: Use with caution in women with active allergic conditions or a history of allergies; use in women with severe allergic conditions is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Exclude pregnancy before beginning treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced specialists: Should only be prescribed by fertility specialists.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F148932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects, including fetal resorption and implantation loss, have been observed in animal reproduction studies. Resorption resulting in fetal loss would be expected if used in a pregnant woman; use is contraindicated during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F148955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4589010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Cetrotide Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (1): $181.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (1): $906.96",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F148924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ultrasound to assess follicle size",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F148933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cetrotide (AR, AT, AU, BE, BG, BR, CH, CL, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IN, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TR, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F148914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with naturally-occurring GnRH for binding on receptors of the pituitary. This delays luteinizing hormone surge, preventing ovulation until the follicles are of adequate size.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F148930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 0.25 mg dose: 2 hours; 3 mg dose: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3 mg dose (single dose): 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 86%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Transformed by peptidases; cetrorelix and peptides (1-9), (1-7), (1-6), and (1-4) are found in the bile; peptide (1-4) is the predominant metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.25 mg dose: 5 hours; 0.25 mg multiple doses: 20.6 hours; 3 mg dose: 62.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 0.25 mg dose: 1 hour; 3 mg dose: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (5% to 10% as unchanged drug and metabolites); urine (2% to 4% as unchanged drug); within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8721 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22580=[""].join("\n");
var outline_f22_3_22580=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148947\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148948\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148972\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148951\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148952\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148953\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676114\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148926\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148911\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148928\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148927\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148970\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148931\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148915\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299005\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148920\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148922\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148932\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148955\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589010\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148924\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148933\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148914\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148930\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8721|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/15/37108?source=related_link\">",
"      Cetrorelix: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_3_22581="Ramipril and hydrochlorothiazide: Patient drug information";
var content_f22_3_22581=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ramipril and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/3/25655?source=see_link\">",
"     see \"Ramipril and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4845310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Altace&reg; HCT;",
"     </li>",
"     <li>",
"      PMS-Ramipril HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ramipril, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries, other kidney disease, or hyperaldosteronism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11908 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22581=[""].join("\n");
var outline_f22_3_22581=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4845310\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019866\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019868\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019867\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019872\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019873\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019875\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019870\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019871\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019876\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019877\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/3/25655?source=related_link\">",
"      Ramipril and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_3_22582="Urea: Drug information";
var content_f22_3_22582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Urea: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/6/19556?source=see_link\">",
"    see \"Urea: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aluvea&trade;;",
"     </li>",
"     <li>",
"      Aqua Care&reg; [OTC];",
"     </li>",
"     <li>",
"      Aquaphilic&reg; with Carbamide [OTC];",
"     </li>",
"     <li>",
"      BP 50%;",
"     </li>",
"     <li>",
"      Carmol&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Carmol&reg; 20 [OTC];",
"     </li>",
"     <li>",
"      Carmol&reg; 40;",
"     </li>",
"     <li>",
"      Carmol&reg; Deep Cleansing [OTC];",
"     </li>",
"     <li>",
"      DPM&trade; [OTC];",
"     </li>",
"     <li>",
"      Gordon's&reg; Urea [OTC];",
"     </li>",
"     <li>",
"      Gormel&reg; Ten [OTC];",
"     </li>",
"     <li>",
"      Gormel&reg; [OTC];",
"     </li>",
"     <li>",
"      Hydro 35&trade;;",
"     </li>",
"     <li>",
"      Hydro 40&trade;;",
"     </li>",
"     <li>",
"      Kerafoam&reg;;",
"     </li>",
"     <li>",
"      Kerafoam&reg; 42;",
"     </li>",
"     <li>",
"      Keralac&trade;;",
"     </li>",
"     <li>",
"      Keralac&trade; Nailstik;",
"     </li>",
"     <li>",
"      Kerol&trade;;",
"     </li>",
"     <li>",
"      Kerol&trade; AD;",
"     </li>",
"     <li>",
"      Kerol&trade; Redi-Cloths;",
"     </li>",
"     <li>",
"      Kerol&trade; ZX;",
"     </li>",
"     <li>",
"      Lanaphilic&reg; with Urea [OTC];",
"     </li>",
"     <li>",
"      Nutraplus&reg; [OTC];",
"     </li>",
"     <li>",
"      Quinnostik;",
"     </li>",
"     <li>",
"      Rea Lo&reg; 30 [OTC];",
"     </li>",
"     <li>",
"      Rea Lo&reg; 40;",
"     </li>",
"     <li>",
"      Remeven&trade;;",
"     </li>",
"     <li>",
"      RevitaDERM&reg; 40;",
"     </li>",
"     <li>",
"      Ultra Mide 25&reg; [OTC];",
"     </li>",
"     <li>",
"      Umecta PD&trade;;",
"     </li>",
"     <li>",
"      Umecta&reg;;",
"     </li>",
"     <li>",
"      Umecta&reg; Nail Film;",
"     </li>",
"     <li>",
"      Uramaxin&reg;;",
"     </li>",
"     <li>",
"      Uramaxin&reg; GT;",
"     </li>",
"     <li>",
"      Uramaxin&reg; GT Kit;",
"     </li>",
"     <li>",
"      Ureacin-10&reg; [OTC];",
"     </li>",
"     <li>",
"      Ureacin-20&reg; [OTC];",
"     </li>",
"     <li>",
"      X-Viate&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      UltraMide 25&trade;;",
"     </li>",
"     <li>",
"      Uremol&reg;;",
"     </li>",
"     <li>",
"      Urisec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Osmotic;",
"     </li>",
"     <li>",
"      Keratolytic Agent;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hyperkeratotic conditions, dry skin:",
"     </b>",
"     Topical: Apply 1-3 times/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydro 35&trade;: 35% (150 g) [contains lactic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydro 40&trade;: 40% (150 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerafoam&reg; 42: 42% (60 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerafoam&reg;: 30% (60 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Umecta&reg;: 40% (113.4 g) [contains soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uramaxin&reg;: 20% (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cloth, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerol&trade; Redi-Cloths: 42% (30s) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 40% (28 g, 30 g, 85 g, 199 g, 210 g); 45% (255 g); 50% (142 g, 255 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aluvea&trade;: 39% (227 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aqua Care&reg;: 10% (71 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carmol&reg; 20: 20% (90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carmol&reg; 40: 40% (28 g, 85 g, 199 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DPM&trade;: 20% (118 g) [contains menthol, peppermint oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gordon's&reg; Urea: 40% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gormel&reg;: 20% (75 g, 120 g, 454 g, 2270 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keralac&trade;: 50% (142 g, 255 g) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutraplus&reg;: 10% (85 g, 90 g [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rea Lo&reg; 30: 30% (60 g, 240 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rea Lo&reg; 40: 40% (60 g, 240 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remeven&trade;: 50% (142 g, 255 g) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RevitaDERM&reg; 40: 40% (112 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uramaxin&reg;: 45% (255 g) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ureacin-20&reg;: 20% (113 g) [contains lactic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     X-Viate&trade;: 40% (29 g, 85 g, 199 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, topical: 50% (284 g, 300 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP 50%: 50% (300 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerol&trade;: 50% (284 g) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerol&trade; AD: 45% (240 mL) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Umecta PD&trade;: 40% (198.5 g) [contains soy; contains sodium hyaluronate 0.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Umecta&reg;: 40% (114 g, 227 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 40% (15 mL); 45% (28 mL); 50% (18 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carmol&reg; 40: 40% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keralac&trade;: 50% (18 mL) [contains lactic acid, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uramaxin&reg;: 45% (28 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uramaxin&reg; GT: 45% (20 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uramaxin&reg; GT Kit: 45% (20 mL) [contains menthol; kit includes Keradan&trade; cream]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     X-Viate&trade;: 40% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 35% (207 mL, 325 mL); 40% (237 mL [DSC]); 45% (454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aqua Care&reg;: 10% (240 mL) [contains lactic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carmol&reg; 10: 10% (180 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carmol&reg; 40: 40% (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gormel&reg; Ten: 20% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keralac&trade;: 35% (207 mL [DSC], 325 mL [DSC]) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutraplus&reg;: 10% (240 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultra Mide 25&reg;: 25% (236 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uramaxin&reg;: 45% (480 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ureacin-10&reg;: 10% (237 mL) [contains lactic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     X-Viate&trade;: 40% (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 50% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquaphilic&reg; with Carbamide: 10% (180 g, 454 g); 20% (454 g) [contains lactic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keralac&trade;: 50% (45 g) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanaphilic&reg; with Urea: 10% (454 g); 20% (454 g) [contains lactic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carmol&reg; Deep Cleansing: 10% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 50% (2.4 mL, 12 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keralac&trade; Nailstik: 50% (2.4 mL) [contains lactic acid, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerol&trade; ZX: 50% (12 mL) [contains lactic acid, vitamin E, zinc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quinnostik: 50% (2.4 mL) [contains lactic acid, zinc; part of RINNOVI Nail System]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, topical: 40% (18 mL); 50% (284 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerol&trade;: 50% (284 g) [contains lactic acid, salicylic acid, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Umecta PD&trade;: 40% (255.1 g) [contains soy; contains sodium hyaluronate 0.3%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Umecta&reg;: 40% (283 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Umecta&reg; Nail Film: 40% (3 mL, 18 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes foam, cloth, shampoo",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Keratolytic agent to soften nails or skin; OTC: Moisturizer for dry, rough skin",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Local: Transient stinging, local irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to urea or any component of the formulation; viral skin disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate application: Urea should not be used near the eyes. Use with caution if applied to face or broken or inflamed skin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13334386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with all products. When conducted, adverse events were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F232459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F232449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Aluvea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     39% (227 g): $397.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Atrac-Tain External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (57 g): $7.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Carmol 20 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (85 g): $17.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Nutraplus External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (85 g): $13.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Rea-Lo External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30% (60 g): $11.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Remeven External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (142 g): $39.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (U-Kera E External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (85.05 g): $77.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Uramaxin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45% (255 g): $246.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Urea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (85 g): $9.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     39% (227 g): $350.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (198.6 g): $125.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45% (255 g): $171.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (142 g): $113.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (X-Viate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (85 g): $32.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Umecta External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (120 g): $185.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Umecta PD External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-0.3% (198.5 g): $255.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Urea in Zn Undecyl-Lactic Acid External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (300 g): $237.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Hydro 35 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35% (150 g): $250.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Hydro 40 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (150 g): $247.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Kerafoam 42 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     42% (60 g): $175.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Kerafoam External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30% (60 g): $166.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Umecta Mousse External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (113.4 g): $220.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Uramaxin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (100 g): $156.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Cerovel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (25 mL): $105.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Uramaxin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45% (28 mL): $247.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Urea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (15 mL): $121.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (X-Viate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (15 mL): $52.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Rinnovi Nail System External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (74.4 mL): $188.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Uramaxin GT External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45% (1): $277.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Atrac-Tain External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (118 mL): $5.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Carmol 10 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (177 mL): $18.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Cerovel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (325 mL): $94.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Nutraplus External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (236 mL): $14.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Rea-Lo External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (120 mL): $5.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Ultra Mide 25 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (236 mL): $27.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Uramaxin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45% (480 g): $273.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Urea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (240 mL): $9.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (236.6 mL): $52.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45% (480 g): $186.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (X-Viate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (237 mL): $52.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Aquaphilic/Carbamide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (180 g): $6.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (454 g): $12.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Gordons Urea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22% (30 g): $17.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (30 g): $53.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Lanaphilic/Urea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (454 g): $12.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (454 g): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Carmol External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (240 mL): $33.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Uramaxin GT External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45% (20 mL): $234.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Umecta External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (283.4 g): $291.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Umecta Nail Film External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (3 g): $40.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (18 mL): $245.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Umecta PD External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-0.3% (255.1 g): $262.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Urea External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (283.4 g): $122.12",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F232450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alphadrate (NL);",
"     </li>",
"     <li>",
"      Aquacare HP (AU, NZ);",
"     </li>",
"     <li>",
"      Aquadrate (GB, IE);",
"     </li>",
"     <li>",
"      Aqurea (SG);",
"     </li>",
"     <li>",
"      Balisa (DE);",
"     </li>",
"     <li>",
"      Banjil (KP);",
"     </li>",
"     <li>",
"      Basodexan (DE);",
"     </li>",
"     <li>",
"      Calmurid (BE, DE, LU, NL, PT);",
"     </li>",
"     <li>",
"      Calmuril (FI, SE);",
"     </li>",
"     <li>",
"      Carbaderm (NO);",
"     </li>",
"     <li>",
"      Carbaderme (PT);",
"     </li>",
"     <li>",
"      Carbamid (LU);",
"     </li>",
"     <li>",
"      Carbamid Widmer (DE);",
"     </li>",
"     <li>",
"      Carmed (ID);",
"     </li>",
"     <li>",
"      Caruderma (HK);",
"     </li>",
"     <li>",
"      Dermadrate Dry Skin Treatment Cream (SG);",
"     </li>",
"     <li>",
"      DiabeDerm (TH);",
"     </li>",
"     <li>",
"      Elacutan (DE, PL);",
"     </li>",
"     <li>",
"      Eucerin (DE);",
"     </li>",
"     <li>",
"      Euderm (HK, MY, SG);",
"     </li>",
"     <li>",
"      Fenuril (FI);",
"     </li>",
"     <li>",
"      Fuyunhon (HK);",
"     </li>",
"     <li>",
"      Helicobacter Test Infai (IT);",
"     </li>",
"     <li>",
"      Hyanit (DE);",
"     </li>",
"     <li>",
"      Hydromol Intensive (GB);",
"     </li>",
"     <li>",
"      Keratinamin (JP);",
"     </li>",
"     <li>",
"      Laceran (DE, PT);",
"     </li>",
"     <li>",
"      Linola Urea (DE);",
"     </li>",
"     <li>",
"      Nubral (AT, DE);",
"     </li>",
"     <li>",
"      Nutraplus (AU, CH, MX, MY, NZ, SG, TH, TW);",
"     </li>",
"     <li>",
"      Onychomal (DE, LU);",
"     </li>",
"     <li>",
"      Pastaron (JP);",
"     </li>",
"     <li>",
"      Penaderm (DE);",
"     </li>",
"     <li>",
"      Runbao (CL);",
"     </li>",
"     <li>",
"      Sebexol (DE);",
"     </li>",
"     <li>",
"      Soft U Derm Forte (ID);",
"     </li>",
"     <li>",
"      Uramol (CN, PE);",
"     </li>",
"     <li>",
"      Ureadin (ES);",
"     </li>",
"     <li>",
"      Urealeti (EC);",
"     </li>",
"     <li>",
"      Urecare (HK, SG);",
"     </li>",
"     <li>",
"      Urederm (AU);",
"     </li>",
"     <li>",
"      Urelac (CO);",
"     </li>",
"     <li>",
"      Uremol (AR);",
"     </li>",
"     <li>",
"      Ureotop (DE);",
"     </li>",
"     <li>",
"      Uricrim (VE);",
"     </li>",
"     <li>",
"      Zoria (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Urea softens hyperkeratotic areas by dissolving the intracellular matrix, resulting in loosening the horny layer of the skin, or softening and debridement of the nail plate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10031 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22582=[""].join("\n");
var outline_f22_3_22582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232453\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232454\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232482\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232456\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232457\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232445\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232434\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232446\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232480\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232448\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232438\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300195\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223591\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232442\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334386\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232459\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232449\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232450\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232437\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/6/19556?source=related_link\">",
"      Urea: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_3_22583="Treatment and prevention of hepatitis D virus infection";
var content_f22_3_22583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of hepatitis D virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22583/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22583/contributors\">",
"     Francesco Negro, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22583/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22583/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22583/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22583/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22583/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/3/22583/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of hepatitis D virus (HDV) infection vary from benign acute hepatitis to fulminant hepatitis, and from an asymptomatic carrier state to rapidly progressive chronic liver disease. HDV is a defective virus requiring the simultaneous presence of hepatitis B virus (HBV) to fully express its pathogenicity; thus, hepatitis D always occurs in the presence of HBV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases of HDV infection, HBV replication is suppressed to low levels by HDV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Liver damage in these patients is essentially due to HDV only. Occasionally, HBV and HDV replicate simultaneously, each virus contributing to the liver damage, thereby resulting in more severe liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE OF HDV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course is influenced by several factors, including the HDV genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/4\">",
"     4",
"    </a>",
"    ]. This issue is discussed in detail elsewhere but a brief review is warranted to provide the rationale for antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predominant genotype in the Western world is genotype I. Once chronic HDV infection is established, it usually exacerbates the preexisting liver disease due to HBV. Progression towards cirrhosis may be rapid, but does not occur in all patients. HDV-associated chronic liver disease may run an indolent course and asymptomatic HDV carriers have been found in some geographical areas.",
"   </p>",
"   <p>",
"    Patients who are currently referred for HDV infection appear to represent cohorts infected many years ago in whom the HDV-related disease rapidly developed to cirrhosis, but whose subsequent disease progression has been slow. This was illustrated in a report from Italy in which the estimated 5- and 10-year probability of survival free of liver transplantation in patients who had already developed clinically overt cirrhosis was 49 and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/5\">",
"     5",
"    </a>",
"    ]. A more ominous course toward liver decompensation has been documented in patients with active HBV and HDV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/5\">",
"     5",
"    </a>",
"    ]. In the Far East, where the predominant genotype is genotype II, there is a less frequent association of chronic HDV infection with progressive liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AIMS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of treatment of hepatitis D is to eradicate or to achieve long-term suppression of both HDV and HBV.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary endpoint of treatment is the suppression of HDV replication, which is accompanied by normalization of the serum aminotransferase (ALT) level and amelioration of necroinflammatory activity on liver biopsy. Suppression of HDV replication is documented by loss of detectable HDV RNA in serum and of HDAg in the liver. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=see_link\">",
"       \"Diagnosis of hepatitis D virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A secondary endpoint is the eradication of HBV infection, with HBsAg to anti-HBs seroconversion. There is very little information to support that current treatment is effective in achieving this goal. Eradication of HBV infection with development of anti-HBs will protect the individual from reinfection with HBV as well as HDV. Patients who have cleared HDV but who remain HBsAg positive are still at risk of reinfection with HDV. This phenomenon has been observed in chimpanzees. However, reexposure to HDV appears to cause only a mild and self-limiting hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTERFERON ALFA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only drug approved at present for treatment of chronic hepatitis D is interferon alfa (IFNa). Peginterferon appears to be more effective than standard interferon, but data are limited. Unfortunately, only a minority of patients treated with interferon clear HDV infection. A meta-analysis of five trials comparing interferon with observation (including a total of 169 participants) concluded that there was a modest benefit in suppressing viral and liver disease activity in some patients, but such benefits were not sustained in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of IFNa in hepatitis D is unclear. IFNa does not have any antiviral activity against HDV when tested in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Thus, the efficacy of IFNa in patients with chronic hepatitis D may depend upon its antiviral effects on the helper virus (HBV) or its immunomodulatory effects. Interestingly, in vitro studies have found that HDV subverts the effect of IFNa signaling, possibly contributing to viral persistence and treatment resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trials of standard interferon therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute number of reported patients with chronic hepatitis D who have been treated with standard IFNa is small and the available data have shown mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/11-18\">",
"     11-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eradication of HDV infection and resolution of liver disease after IFNa treatment have been reported anecdotally in uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In one of these reports, long-term therapy with high doses of IFNa permanently suppressed HDV replication in some patients and dramatically improved liver fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the favorable effects of IFNa have not been confirmed in all controlled trials.",
"   </p>",
"   <p>",
"    In the largest multicenter trial, 61 Italian patients with chronic hepatitis D were randomly assigned to receive IFNa in doses of 5",
"    <span class=\"nowrap\">",
"     MU/m2",
"    </span>",
"    three times weekly for four months, followed by 3",
"    <span class=\"nowrap\">",
"     MU/m2",
"    </span>",
"    three times weekly for an additional eight months, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/14\">",
"     14",
"    </a>",
"    ]. They were then followed for another 12 months. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eight (25 percent) of the 31 treated patients had a normal serum ALT level versus none of the 30 controls at the end of the 12-month treatment period. However, all but one of the responders had biochemical relapse after discontinuation of therapy. Only one patient had a normal ALT level at the end of the follow-up period.",
"     </li>",
"     <li>",
"      Fourteen (45 percent) treated patients were HDV RNA-negative at the end of treatment; however, a similar proportion (27 percent) of controls also became HDV RNA-negative, suggesting that spontaneous fluctuations in HDV viremia may occur. The frequency of undetectable HDV-RNA at the end of the follow-up period was not significantly different (45 versus 33 percent with placebo). The only patient with persistently normal ALT level was also HDV RNA-negative at the end of the follow-up period.",
"     </li>",
"     <li>",
"      Improvement in liver histology at the end of therapy occurred with similar frequency in the two groups (57 versus 36 percent, p = NS).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that IFNa therapy did not produce any appreciable benefit in patients with chronic hepatitis D.",
"   </p>",
"   <p>",
"    In another smaller Italian study, 42 patients with chronic hepatitis D were randomly assigned to receive two different doses (9 versus 3 MU three times weekly) of IFNa for 48 weeks or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal serum ALT levels at the end of treatment occurred more frequently in the patients receiving 9 MU doses of IFNa than in the other two groups (70, 29, and 8 percent, respectively).",
"     </li>",
"     <li>",
"      Complete response (normal ALT level and undetectable serum HDV RNA at the end of treatment) was also more frequent with 9 MU dosing (50, 21, and 0 percent, respectively).",
"     </li>",
"     <li>",
"      Treatment with 9 MU doses of IFNa was also associated with a marked improvement in liver histology. Five of the 10 responders in the 9 MU dose group had normal ALT levels that lasted for up to four years. However, none of the patients had sustained clearance of HDV RNA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that high-dose interferon was effective in suppressing HDV replication but that the antiviral effect was not sustained. Furthermore, in a follow-up report they found that ALT normalization correlated with improved hepatic function and loss of IgM anti-HDV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/16\">",
"     16",
"    </a>",
"    ]. Compared to treatment with low-dose interferon or placebo, those who received high doses of IFNa were more likely to have clearance of HDV RNA and HBV DNA as well as improvement in histologic activity and fibrosis (including reversal of cirrhosis in some patients).",
"   </p>",
"   <p>",
"    However, these optimistic conclusions have not been confirmed by another randomized, controlled trial performed in Italy that used a similarly aggressive regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/17\">",
"     17",
"    </a>",
"    ]. The reasons for these discrepant findings are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Factors predicting response to standard IFNa",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the poor overall response, it is difficult to identify factors that predict response. The only feature that may be associated with an increased likelihood of response is a short duration of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/11,12,14\">",
"     11,12,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peginterferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little published experience with peginterferon in the treatment of chronic hepatitis D [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The largest published study included 38 patients who were treated with pegylated IFN alfa-2b (1.5",
"    <span class=\"nowrap\">",
"     MU/kg",
"    </span>",
"    per week) alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/19\">",
"     19",
"    </a>",
"    ]. Most patients had previously failed treatment with standard IFN. All patients were maintained on pegylated IFN for an additional 24 weeks, and then followed off therapy for 24 weeks. At the end of follow-up, HDV RNA was undetectable in eight patients (21 percent). Treatment had to be discontinued in 25 percent of patients while 58 percent required dose modification. The response rate was similar in the monotherapy and combination therapy groups suggesting that ribavirin had no effect on the viral clearance rate. The response rate was somewhat higher in a subset of patients who had not previously received interferon-based therapy (three of eight patients).",
"   </p>",
"   <p>",
"    A higher virologic response rate (43 percent) was found in another study involving 14 patients treated with 12 months of pegylated IFN [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/20\">",
"     20",
"    </a>",
"    ]. The higher response rate may have been due to a lower proportion of patients with cirrhosis in the second study (28 versus 74 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Peginterferon plus adefovir dipivoxil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have evaluated combination therapy for HDV using nucleoside analogues. One of the largest controlled trials included 90 patients with compensated chronic hepatitis D who were randomly assigned to peginterferon alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , or adefovir monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/22\">",
"     22",
"    </a>",
"    ]. After 48 weeks, HDV RNA was negative in approximately 25 percent of patients in both peginterferon arms and none in the adefovir monotherapy arm. The response was sustained up to 24 weeks after stopping therapy. Thus, combination therapy appeared to offer no advantage to peginterferon monotherapy, while adefovir monotherapy was ineffective. A significant decline in HBsAg levels was observed in patients receiving peginterferon (especially when combined with adefovir) but not in patients treated with adefovir monotherapy, the clinical significance of which requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ALTERNATIVE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs have been evaluated as alternatives to interferon. Overall, the results are discouraging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       Ribavirin",
"      </a>",
"      inhibits HDV replication in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/23\">",
"       23",
"      </a>",
"      ]. It has been tested in two small trials in humans without any biochemical or virological response [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. The addition of ribavirin to pegylated IFNa did not improve response [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      have a paradoxical stimulatory effect on HDV replication, at least in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/23\">",
"       23",
"      </a>",
"      ]. However, anecdotal reports suggest that foscarnet may be beneficial in fulminant liver failure due to",
"      <span class=\"nowrap\">",
"       HBV/HDV",
"      </span>",
"      coinfection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment of acute hepatitis D'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/50/30498?source=see_link\">",
"       Suramin",
"      </a>",
"      inhibits HDV infection in vitro, possibly by blocking virus uptake or uncoating [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/23,26\">",
"       23,26",
"      </a>",
"      ]. When administered in vivo, suramin was effective in preventing HDV infection in woodchucks only when they were inoculated with a low infecting dose [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      THF gamma 2, a synthetic octapeptide of thymic origin, has been shown to have some efficacy in HBV infection. However, a pilot study in 11 patients with hepatitis D found that it was ineffective [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      , a potent inhibitor of HBV replication, had little or no effect on HDV replication in two series [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/29,30\">",
"       29,30",
"      </a>",
"      ], and no synergistic effect with high dose IFNa in two other reports [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antisense oligonucleotides are nucleic acid sequences that bind to RNA or DNA with a high degree of specificity, and can thereby block expression of a specific protein. Antisense therapy is being developed for treatment of HDV, but its efficacy has not yet been established [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Prenylation\" involves the covalent addition of a farnesyl or geranylgeranyl isoprenoid molecule to a conserved cysteine residue at or near the C-terminus of a protein [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/34\">",
"       34",
"      </a>",
"      ]. This link promotes membrane interactions with the prenylated protein, since the isoprenoid chain is hydrophobic. Specific inhibitors of HDV prenylation have been developed. In particular, the farnesyltransferase inhibitor FTI-277 prevented the production of complete infectious HDV virions of different genotypes, including the genotypes associated with most severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/35\">",
"       35",
"      </a>",
"      ]. The prenylation inhibitors FTI-277 and FTI-2153 were highly effective in clearing HDV viremia in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      , an acyclic deoxyguanosine analog, was of no benefit in a pilot study [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACUTE HEPATITIS D",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for acute hepatitis D. In one report, all three patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    for fulminant hepatitis due to HDV recovered, as did two additional patients with fulminant hepatitis due to HBV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/38\">",
"     38",
"    </a>",
"    ]. Although these results are encouraging, they need to be confirmed. Foscarnet is an inhibitor of some viral DNA polymerases. However, it was shown to have a paradoxical stimulatory effect on HDV replication in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, the efficacy of foscarnet in fulminant hepatitis due to",
"    <span class=\"nowrap\">",
"     HBV/HDV",
"    </span>",
"    coinfection may be secondary to its inhibition of HBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION OF HDV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of prevention of HDV infection is vaccination against its helper virus, the HBV. Anti-HBs-positive chimpanzees are protected against experimental HDV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/39\">",
"     39",
"    </a>",
"    ]. However, passive prophylaxis with hepatitis B immunoglobulin has not completely prevented reinfection of transplanted livers by HDV. In some patients, HDV virions were able to infect and replicate within the liver allograft. Nonetheless, HDV infection is abortive and does not result in recurrent liver disease unless the allograft is simultaneously reinfected with HBV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3543?source=see_link\">",
"     \"Hepatitis D virus reinfection following liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vaccination against HDV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic HBV infection is a serious health problem affecting approximately 300 million individuals worldwide. Apart from the morbidity and mortality associated with HBV infection, these individuals are at risk of HDV infection. Thus, every effort should be made to reduce the risk of HDV transmission to HBV carriers. The observation that chimpanzees rechallenged with HDV many years after recovery from the initial HDV infection were partially protected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/6\">",
"     6",
"    </a>",
"    ] suggests that a protective immune response is present and that vaccine strategies for preventing HDV superinfection may be feasible.",
"   </p>",
"   <p>",
"    Early attempts to vaccinate woodchuck hepatitis virus (WHV) carrier woodchucks with liver derived HDAg [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/40\">",
"     40",
"    </a>",
"    ] or the N-terminal portion of recombinant HDAg that contain a major immunogenic epitope [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/41\">",
"     41",
"    </a>",
"    ] were unsuccessful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\", section on 'Hepatitis D antigen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a later experiment, six WHV carrier woodchucks were repeatedly immunized with the full-size, recombinant, yeast-derived small form of HDAg [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/42\">",
"     42",
"    </a>",
"    ]. Upon challenge with HDV, two woodchucks were not infected, as serum HDV RNA was never detected by polymerase chain reaction; two showed a transient, low level HDV viremia, and only two had a typical acute HDV infection. All control animals developed full-blown acute hepatitis D. These data showed for the first time that partial protection against HDV superinfection could be achieved by active immunization.",
"   </p>",
"   <p>",
"    A similar study used the short form of HDAg expressed by recombinant baculovirus or vaccinia virus as immunogen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/43\">",
"     43",
"    </a>",
"    ]. Again, after challenge of the woodchucks with HDV, partial protection was observed even though anti-HDV was not detected. It is possible that the protection was related to induction of cytotoxic T-cell response.",
"   </p>",
"   <p>",
"    However, these encouraging results were not confirmed by other investigators who used live recombinant vaccinia virus expressing either the small or the large form of HDAg [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/44\">",
"     44",
"    </a>",
"    ]. The explanations for the different outcomes using vaccines that are manufactured by very similar approaches are unknown.",
"   </p>",
"   <p>",
"    In another approach, three synthetic HDAg peptides were administered to four woodchucks, resulting in the production of specific antibodies. These woodchucks developed transient, low-level viremia after inoculation with HDV but none developed chronic HDV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22583/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, partial protection of HBsAg carriers from HDV infection through active immunization is feasible. The woodchucks serve as a useful animal model for evaluating HDV vaccines. However, worldwide implementation of a vaccination policy against HDV would probably prove too costly and impractical due to the need to screen for HBsAg carriers. Vaccination against HBV remains the most cost effective means to prevent HDV infection, except for individuals who are already infected with HBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the rate of success is low, we suggest that patients with chronic hepatitis D and active liver disease, as evidenced by elevated ALT levels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic hepatitis on liver biopsy be treated and treated early, particularly if there is advanced fibrosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This is based upon the observation that chronic hepatitis D can be a severe liver disease, and that response is more likely to be attained in patients with a short duration of infection. Asymptomatic HDV carriers with normal ALT levels do not require therapy but should be monitored for signs of active disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Aims of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment of HDV is uncertain. Thus, patients should ideally be treated as part of a clinical trial. As noted above, the only treatment approved for chronic HDV is interferon alfa. Before the availability of peginterferon, the recommended dose regimen was standard IFNa 9 MU three times weekly for at least 12 months, although longer treatment had been advocated. However, in light of emerging data, we suggest pegylated IFNa replace standard IFNa as the treatment of choice for chronic hepatitis D (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment should be administered for one year; whether longer duration of treatment will improve response rates remains to be established. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Peginterferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available data have not demonstrated an advantage from the addition of a",
"      <span class=\"nowrap\">",
"       nucleos/tide",
"      </span>",
"      analogue. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Alternative treatments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/1\">",
"      Krogsgaard K, Kryger P, Aldershvile J, et al. Delta-infection and suppression of hepatitis B virus replication in chronic HBsAg carriers. Hepatology 1987; 7:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/2\">",
"      Farci P, Karayiannis P, Lai ME, et al. Acute and chronic hepatitis delta virus infection: direct or indirect effect on hepatitis B virus replication? J Med Virol 1988; 26:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/3\">",
"      Smedile A, Rosina F, Saracco G, et al. Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. Hepatology 1991; 13:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/4\">",
"      Wu JC, Choo KB, Chen CM, et al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995; 346:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/5\">",
"      Rosina F, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999; 117:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/6\">",
"      Negro F, Shapiro M, Satterfield WC, et al. Reappearance of hepatitis D virus (HDV) replication in chronic hepatitis B virus carrier chimpanzees rechallenged with HDV. J Infect Dis 1989; 160:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/7\">",
"      Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011; :CD006002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/8\">",
"      Ilan Y, Klein A, Taylor J, Tur-Kaspa R. Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells. J Infect Dis 1992; 166:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/9\">",
"      McNair AN, Cheng D, Monjardino J, et al. Hepatitis delta virus replication in vitro is not affected by interferon-alpha or -gamma despite intact cellular responses to interferon and dsRNA. J Gen Virol 1994; 75 ( Pt 6):1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/10\">",
"      Pugnale P, Pazienza V, Guilloux K, Negro F. Hepatitis delta virus inhibits alpha interferon signaling. Hepatology 2009; 49:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/11\">",
"      Lau JY, King R, Tibbs CJ, et al. Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection. J Med Virol 1993; 39:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/12\">",
"      Battegay M, Simpson LH, Hoofnagle JH, et al. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol 1994; 44:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/13\">",
"      Lau DT, Kleiner DE, Park Y, et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999; 117:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/14\">",
"      Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/15\">",
"      Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/16\">",
"      Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126:1740.",
"     </a>",
"    </li>",
"    <li>",
"     Borghesio E, Rosina F, Di Marco V, et al. Long-term treatment of chronic hepatitis D with lymphoblastoid interferon: 10 MU vs. 5 MU. An interim report of a randomized controlled trial. Proceedings of the Fifth International Symposium on Hepatitis Delta Virus and Liver Disease. Brisbane, August 28-29, 1995; D47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/18\">",
"      Gaudin JL, Faure P, Godinot H, et al. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/19\">",
"      Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/20\">",
"      Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/21\">",
"      Ferenci P, Formann E, Romeo R. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a. Am J Gastroenterol 2005; 100:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/22\">",
"      Wedemeyer H, Yurdayd&igrave;n C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322.",
"     </a>",
"    </li>",
"    <li>",
"     Rasshofer R, Choi SS, Wolfl P, et al. Inhibition of HDV RNA replication in vitro by ribavirin and suramin. In: Viral Hepatitis and Liver Disease, Hollinger FB, Lemon SM, Margolis HS (Eds), Williams &amp; Wilkins, Baltimore 1991. p.659.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/24\">",
"      Buti M, Lopez-Talavera JC, Allende H, et al. Serological diagnosis of chronic delta infection: correlation between serological markers and hepatitis delta virus RNA in hepatic tissue. Prog Clin Biol Res 1993; 382:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/25\">",
"      Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/26\">",
"      Petcu DJ, Aldrich CE, Coates L, et al. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology 1988; 167:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/27\">",
"      Ponzetto A, Negro F, Gerin JL, Purcell RH. Experimental hepatitis delta virus infection in the animal model. Prog Clin Biol Res 1991; 364:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/28\">",
"      Rosina F, Conoscitore P, Giuliani A, et al. Treatment of chronic hepatitis D with the thymosin derivative THF gamma 2: Results of a pilot study (abstract). Hepatology 1994; 20:309A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/29\">",
"      Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/30\">",
"      Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/31\">",
"      Wolters LM, van Nunen AB, Honkoop P, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000; 7:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/32\">",
"      Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/33\">",
"      Chen TZ, Wu JC, Au LC, Choo KB. Specific inhibition of delta antigen by in vitro system by antisense oligodeoxynucleotide: implications for translation mechanism and treatment. J Virol Methods 1997; 65:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/34\">",
"      Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/35\">",
"      Bordier BB, Marion PL, Ohashi K, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 2002; 76:10465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/36\">",
"      Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/37\">",
"      Yurdaydin C, Bozkaya H, G&uuml;rel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/38\">",
"      Hedin G, Weiland O, Ljunggren K, et al. Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet. Prog Clin Biol Res 1987; 234:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/39\">",
"      Rizzetto M, Canese MG, Gerin JL, et al. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980; 141:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/40\">",
"      Ponzetto A, Forzani B, D'Urso N, et al. Immunization with hepatitis delta antigen does not prevent superinfection with hepatitis delta virus in the woodchuck. Gastroenterology 1989; 96:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/41\">",
"      Karayiannis P, Saldanha J, Monjardino J, et al. Immunization of woodchucks with recombinant hepatitis delta antigen does not protect against hepatitis delta virus infection. Hepatology 1990; 12:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/42\">",
"      Ponzetto A, Eckart M, D'Urso N, et al. Towards a vaccine for the prevention of hepatitis delta virus superinfection in HBV carriers. Prog Clin Biol Res 1993; 382:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/43\">",
"      Karayiannis P, Saldanha J, Jackson AM, et al. Partial control of hepatitis delta virus superinfection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus. J Med Virol 1993; 41:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/44\">",
"      Eckart MR, Dong C, Houghton M, et al. The effects of using recombinant vaccinia viruses expressing either large or small HDAg to protect woodchuck hepadnavirus carriers from HDV superinfection. Prog Clin Biol Res 1993; 382:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22583/abstract/45\">",
"      Bergmann KF, Casey JL, Tennant BC, Gerin JL. Modulation of hepatitis delta virus infection by vaccination with synthetic peptides: a preliminary study in the woodchuck model. Prog Clin Biol Res 1993; 382:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3664 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22583=[""].join("\n");
var outline_f22_3_22583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL COURSE OF HDV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AIMS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTERFERON ALFA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trials of standard interferon therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Factors predicting response to standard IFNa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peginterferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Peginterferon plus adefovir dipivoxil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALTERNATIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF ACUTE HEPATITIS D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION OF HDV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vaccination against HDV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=related_link\">",
"      Diagnosis of hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3543?source=related_link\">",
"      Hepatitis D virus reinfection following liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=related_link\">",
"      Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_3_22584="Type II endometrial carcinomas (eg, serous, clear cell, mucinous)";
var content_f22_3_22584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Type II endometrial carcinomas (eg, serous, clear cell, mucinous)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22584/contributors\">",
"     Peter E Schwartz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22584/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22584/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/3/22584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide in 2008, 287,100 women were diagnosed with uterine cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/1\">",
"     1",
"    </a>",
"    ]. The mortality rate was 1.7 to 2.4 per 100,000 women. In the United States, as with other developed countries, uterine cancer was the most common gynecologic malignancy, with approximately 46,470 new cases and 8120 deaths from the disease in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenocarcinoma of the endometrium (lining of the uterus) is the most common histologic site and type of uterine cancer. Endometrial cancer is often classified into two subtypes (Type I and Type II), which reflect general characteristics of its clinicopathological spectrum. Type II neoplasms are generally associated with more aggressive clinical behavior than type I tumors. While they comprise 10 to 20 percent of endometrial carcinomas, they account for 40 percent of deaths from the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information specific to type II endometrial carcinomas is reviewed here. An overview of endometrial carcinoma can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link\">",
"     \"Overview of endometrial carcinoma\"",
"    </a>",
"    .) Related topics are discussed in detail separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histopathology and pathogenesis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=see_link\">",
"       \"Endometrial carcinoma: Histopathology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidemiology and risk factors (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical features, diagnosis, and screening for high-risk women (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link\">",
"       \"Endometrial carcinoma: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staging and surgical treatment (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"       \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adjuvant therapy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link\">",
"       \"Approach to adjuvant treatment of endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4548929\">",
"    <span class=\"h1\">",
"     HISTOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among endometrial carcinomas, there are two histologic categories, which differ in incidence, responsiveness to estrogens, and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I tumors include tumors of endometrioid histology that are grade 1 or 2; these comprise approximately 80 percent of endometrial carcinomas. These tumors typically have a favorable prognosis, are estrogen-responsive, and may be preceded by an intraepithelial neoplasm (atypical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complex endometrial hyperplasia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link&amp;anchor=H381678#H381678\">",
"       \"Classification and diagnosis of endometrial hyperplasia\", section on 'Risk of carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type II tumors account for 10 to 20 percent of endometrial carcinomas. They include grade 3 endometrioid tumors as well as tumors of non-endometrioid histology: serous, clear cell, mucinous, squamous, transitional cell, mesonephric, and undifferentiated. These tumors are often high-grade, have a poor prognosis, and are not clearly associated with estrogen stimulation. A precursor lesion is rarely identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1962297\">",
"    <span class=\"h2\">",
"     Precursor lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that uterine serous carcinoma (USC) develops from \"endometrial intraepithelial carcinoma\" (EIC), a lesion related to malignant transformation of the endometrial surface epithelium (such as a benign endometrial polyp), against a background of endometrial atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, EIC has been found in association with extrauterine serous carcinoma, with both sites having identical clones of p53 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/8\">",
"     8",
"    </a>",
"    ]. This finding has led some to suggest that EIC represents an early form of USC rather than its true precursor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/9\">",
"     9",
"    </a>",
"    ]. A relatively new entity, \"endometrial glandular dysplasia\", which histologically bridges benign endometrium and EIC, may be the putative precursor lesion to USC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    A putative precursor lesion for endometrial clear cell carcinoma characterized by nuclear atypia has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1962304\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most endometrioid cancers are well-differentiated endometrioid adenocarcinomas, which are characterized by proliferation of back-to-back endometrial glands without intervening stroma. In contrast, USC has a complex papillary architecture that resembles serous carcinoma of the ovary; psammoma bodies are present in 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Marked nuclear atypia is always present, and all USC is considered high-grade.",
"    <br/>",
"    <br/>",
"    Clear cell cancers are characterized by tubulocystic, papillary, or solid patterns; psammoma bodies are present in up to 10 percent of cases, most often in the papillary variant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The cells may be clear because of the presence of glycogen. Myometrial invasion occurs in about 80 percent of cases. At least from the standpoint of gene expression, they appear more similar to clear cell cancers arising in other organs (eg, the kidney) than to other uterine cancers, including those of the serous variety [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/16\">",
"     16",
"    </a>",
"    ]. Nevertheless, they are treated similar to serous cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    USC and clear cell carcinomas may be a component of mixed histology tumors that have endometrioid or sarcomatous elements. If 10 percent or more of the tumor has a serous component, it is classified as USC; cases in which the serous component consists of more than 10 percent but less than 90 percent of the cancer are classified as mixed serous cancers.",
"   </p>",
"   <p>",
"    Earlier studies suggested little difference in survival when patients with pure USC cancers were compared to those with mixed USC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. However, a multi-institutional series comparing 58 patients with mixed USC to 50 patients with pure uterine papillary serous carcinomas found the two most important prognostic factors for progression-free and overall survival were stage and pure USC histology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with pure USC histology had a 2.9-fold greater risk for recurrence and a 2.6-fold higher risk of death compared to those with mixed USC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/21\">",
"     21",
"    </a>",
"    ]. &nbsp;",
"    <br/>",
"    <br/>",
"    For clear cell carcinomas, some pathologists require &ge;50 percent clear cell features to classify a tumor as a clear cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/22\">",
"     22",
"    </a>",
"    ], while others use the benchmark of at least 25 percent clear cell component [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Patients with pure clear cell cancers and mixed clear cell cancers with endometrioid components have the same survival as those whose clear cell cancers contain less histologically favorable components [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1962442\">",
"    <span class=\"h2\">",
"     Biologic behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both USC and clear cell tumors have a higher propensity for lymphovascular invasion, and intraperitoneal as well as extraabdominal spread, than endometrioid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/12,19,22,25-27\">",
"     12,19,22,25-27",
"    </a>",
"    ]. At the time of presentation, approximately 60 to 70 percent of women with USC will have disease spread outside of the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/19,27\">",
"     19,27",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Lymph node metastasis and extrauterine disease spread are extremely rare with endometrioid cancers that are noninvasive; in contrast, they frequently occur with noninvasive USC (ie, EIC). Furthermore, while tumor grade and depth of myometrial invasion are not predictive of extrauterine spread for USC, the incidence of extrauterine spread in endometrioid cancer correlates with both tumor grade and depth of myometrial invasion (",
"    <a class=\"graphic graphic_table graphicRef58580 \" href=\"UTD.htm?15/26/15788\">",
"     table 1",
"    </a>",
"    ).",
"    <br/>",
"    <br/>",
"    In one study, lymph node metastases were found in 36 percent of women with USC and no myometrial invasion, compared to 50 and 46 percent of those with inner one-half, and outer one-half invasion, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/28\">",
"     28",
"    </a>",
"    ]. The corresponding rates of intraperitoneal disease for these three groups were 43, 37, and 35 percent, respectively. Even having as little as 10 percent of the tumor composed of USC places the patient at the same risk for metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1962449\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I and type II uterine tumors also appear to have a different pattern of molecular alterations that underlie pathogenesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/30\">",
"     30",
"    </a>",
"    ]. Alterations in the tumor suppressor gene PTEN, microsatellite instability, and K-ras alterations have been associated with the early development of type I tumors, while these alterations are uncommon in type II cancers. On the other hand, p53 mutations appear to be important in the early pathogenesis of USC. Moreover, HER2",
"    <span class=\"nowrap\">",
"     overexpression/amplification",
"    </span>",
"    has been associated with type II tumors. These issues are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=see_link&amp;anchor=H8#H8\">",
"     \"Endometrial carcinoma: Histopathology and pathogenesis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    There are conflicting data regarding whether USC is one of the spectrum of cancers in women with BRCA1 or 2 gene mutations. Inheritance of these mutations is more common in Jewish women, particularly those of Ashkenazi descent. In one report, 4 of 20 Jewish women with USC had BRCA1 germline mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/31\">",
"     31",
"    </a>",
"    ]. In another, three BRCA1 and three BRCA 2 germline mutations were identified among 22 Jewish women with USC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link&amp;anchor=H2#H2\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'BRCA1 and BRCA2 genes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General principles of the histopathology of endometrial carcinoma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=see_link\">",
"     \"Endometrial carcinoma: Histopathology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4548904\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II endometrial neoplasms account for 10 to 20 percent of endometrial carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Since they are less common, there are fewer epidemiologic data about them than type I carcinomas. General information about the epidemiology of endometrial carcinomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H1#H1\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type II endometrial carcinomas tend to present at an advanced stage. Approximately 70 percent of patients with uterine serous cancer (USC) and 50 percent with clear cell cancers present with stage III or IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/19,33,34\">",
"     19,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type II endometrial carcinomas have traditionally been thought to differ from type I tumors in several ways. Some of these are well established, but others are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/5,35\">",
"     5,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average age at diagnosis is older for type II disease in most studies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/4,36\">",
"       4,36",
"      </a>",
"      ]. However, a prospective study of over one million Norwegian women followed for an average of 25 years, which included 992 type II carcinomas, revealed no difference in age at diagnosis of type I and type II cancers (mean age 65 years both groups) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/37\">",
"       37",
"      </a>",
"      ]. By comparison, the average age at diagnosis of all uterine cancer in the United States is 61 years old [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obesity is a known risk factor for type I endometrial carcinomas and was not thought to be associated with type II [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/5\">",
"       5",
"      </a>",
"      ]. However, there is evidence that obesity is a risk factor for all endometrial carcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/37,39\">",
"       37,39",
"      </a>",
"      ]. As an example, in the Norwegian cohort study cited above, obesity was associated with an increased risk of either type of tumor, but the risk was more pronounced for type I [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with type II tumors are more likely to be parous than nulliparous [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type II tumors have a different racial distribution than type I carcinomas. Among women with endometrial carcinoma, black women are more likely than white women to have type II tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/35,42\">",
"       35,42",
"      </a>",
"      ]. This may contribute to the poorer overall prognosis for black women compared with white women with endometrial carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between breast cancer and USC is uncertain, but it appears that a personal history of breast cancer is associated with a risk of developing USC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/35,45,46\">",
"     35,45,46",
"    </a>",
"    ]. As an example, in a case-control study of women with endometrial carcinoma, women with serous histology were more likely than those with endometrioid histology to have a personal history of breast cancer (19 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/46\">",
"     46",
"    </a>",
"    ]. This risk does not appear to be dependent upon use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . In addition, there have some reports the BRCA1 mutation carriers are at an increased risk of USC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1962449\">",
"     'Molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2028614\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding is the most common clinical presentation for type II endometrial carcinomas, just as with type I tumors. Likewise, some women present with endometrial cells on cervical cytology. The clinical presentation and prediagnostic evaluation of endometrial carcinoma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2028723\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum CA-125 has been used as a circulating tumor marker for the management of women with USC, although the studies looking at its use have been small in number and contradictory. In one study of 51 patients, an elevated preoperative CA-125 was noted in only nine (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/47\">",
"     47",
"    </a>",
"    ]. It appears that elevation of CA-125 is associated with more advanced stage at diagnosis, positive pelvic node involvement, positive peritoneal washings, and the presence of lymphovascular invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/48\">",
"     48",
"    </a>",
"    ]. However, the prognostic effect of an elevated CA-125 on progression-free survival remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. While a correlation between elevated CA-125 preoperatively and lymph node metastases was noted, it was not associated with development of recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2028622\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinoma is a histologic diagnosis made based upon histologic evaluation of endometrial sampling, curettage, or a hysterectomy specimen. This is the same for both type I and type II tumors.",
"   </p>",
"   <p>",
"    An office endometrial biopsy is a sensitive test for type II endometrial carcinomas. However, the correct histology may not be identified in all cases. As an example, in one study, among 67 women with a final postoperative diagnosis of uterine serous carcinoma, 17 were reported as endometrioid histology based upon evaluation of the initial endometrial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/49\">",
"     49",
"    </a>",
"    ]. This may be due to the fact that USC is often found mixed with other high-grade endometrial carcinomas (grade 3 endometrioid or clear cell). There were few cases of a false positive diagnosis of USC (2 of 234 women with a postoperative diagnosis of endometrioid tumors had a biopsy result of USC). &nbsp;",
"   </p>",
"   <p>",
"    Diagnostic methods for endometrial carcinoma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link&amp;anchor=H1268005#H1268005\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STAGING AND SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II endometrial carcinomas are surgically staged in the same manner as type I tumors (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 2",
"    </a>",
"    ). Staging of endometrial cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type II neoplasms are more likely to present at an advanced stage, as noted above, 50 to 70 percent of patients present with stage III or IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/19,33,34\">",
"     19,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal cytoreduction is an important component of surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/34,50-56\">",
"     34,50-56",
"    </a>",
"    ]. The strongest predictor of overall survival is the amount of residual disease following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/34,50-55\">",
"     34,50-55",
"    </a>",
"    ]. As an example, in a retrospective review of 70 women with stage IIIC or IV USC, median survival was significantly longer after optimal cytoreduction with no visible residual disease, as compared to optimal cytoreduction with macroscopic residual disease and suboptimal cytoreduction (51 versus 14 and 12 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/50\">",
"     50",
"    </a>",
"    ]. Outcomes in the group with residual disease were not substantially improved by the use of postoperative chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2028630\">",
"    <span class=\"h1\">",
"     ADJUVANT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II endometrial carcinomas are high-risk disease. Treatment of high-risk disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link\">",
"     \"Adjuvant treatment of high-risk endometrial cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27281460\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II endometrial carcinomas have been associated with a poorer outcome than type I tumors, in most, but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/19,24,25,28,57-61\">",
"     19,24,25,28,57-61",
"    </a>",
"    ], although at least one study from the Gynecologic Oncology Group suggested the association between tumor type and prognosis was weak for patients with",
"    <span class=\"nowrap\">",
"     advanced/recurrent",
"    </span>",
"    endometrial cancer. As an example, in a study of 4180 women with high-risk endometrial carcinoma subtypes reported to the Surveillance, Epidemiology and End Results (SEER) United States national cancer database between 1988 and 2001, uterine serous carcinoma (USC) and clear cell carcinoma accounted for 10 and 3 percent of all endometrial carcinomas, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/60\">",
"     60",
"    </a>",
"    ]. However, they were responsible for 39 and 8 percent of all deaths. The five-year disease-specific survival rates for USC and clear cell were 55 and 68, respectively. These statistics were confirmed in the latest survival data from the International Federation of Gynecology and Obstetrics (",
"    <a class=\"graphic graphic_table graphicRef73803 \" href=\"UTD.htm?5/56/6028\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/59\">",
"     59",
"    </a>",
"    ]. The five-year survival rates for USC or clear cell cancer were 72 and 80 percent, respectively; the corresponding value for endometrioid cancers was 89 percent.",
"   </p>",
"   <p>",
"    Even among women with completely surgically staged, node-negative, stage I USC, the five-year overall survival rate is approximately 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/58\">",
"     58",
"    </a>",
"    ]. Women with clear cell carcinoma have a similar prognosis; five-year overall survival is estimated at 62.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27282012\">",
"    <span class=\"h2\">",
"     HER2 amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overexpression or amplification of HER2 (erbB-2, the epidermal growth factor type II receptor) has been identified in a number of studies as a poor prognostic sign for type II endometrial carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/62-67\">",
"     62-67",
"    </a>",
"    ]. This was illustrated in a series of 30 women undergoing treatment for stage IA to IV USC (25 with stage III or IV disease) at a single institution over a seven-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/62\">",
"     62",
"    </a>",
"    ]. Amplification of the HER2 gene, as detected by fluorescence in situ hybridization (FISH) was observed in 14 (47 percent), with more tumors arising from African American women positive (67 percent) compared to those arising in Caucasian women (33 percent). At four years, disease-specific survival rates were 17 and 84 percent for those with FISH-positive and FISH-negative tumors, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119718345\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clear cell carcinomas are more likely than either endometrioid cancers or uterine serous carcinomas to recur with distant spread (eg, to the lungs and bones) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22584/abstract/23\">",
"     23",
"    </a>",
"    ]. The recurrence pattern of serous endometrial cancer is similar to epithelial ovarian cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H39#H39\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Posttreatment surveillance protocols are the same for type II as type I endometrial carcinomas. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H11157097#H11157097\">",
"     \"Overview of endometrial carcinoma\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenocarcinoma of the endometrium (lining of the uterus) is the most common histologic site and type of uterine cancer. There are two histologic categories of endometrial carcinoma: type I (endometrioid) and type II (eg, serous, clear cell). (See",
"      <a class=\"local\" href=\"#H4548929\">",
"       'Histology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type II neoplasms are generally associated with more aggressive clinical behavior than type I tumors. Approximately 70 percent of patients with uterine serous cancer (USC) and 50 percent with clear cell cancers present with stage III or IV disease. While they comprise 10 to 20 percent of endometrial carcinomas, type II tumors account for 40 percent of deaths from the disease. (See",
"      <a class=\"local\" href=\"#H1962442\">",
"       'Biologic behavior'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with type II endometrial carcinoma have different characteristics than those with endometrioid tumors. They tend to be older at diagnosis, non-obese, and parous. A personal history of breast cancer appears to be a risk factor for USC. (See",
"      <a class=\"local\" href=\"#H4548904\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial carcinoma is a histologic diagnosis made based upon histologic evaluation of endometrial sampling, curettage, or a hysterectomy specimen. (See",
"      <a class=\"local\" href=\"#H2028622\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type II endometrial carcinomas are surgically staged in the same manner as type I tumors (",
"      <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"       table 2",
"      </a>",
"      ). Surgical staging is recommended for all Type II tumors because of the high risk of nodal and extrauterine metastasis. Optimal cytoreduction is an important component of surgical treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Staging and surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overexpression or amplification of HER2 (erbB-2, the epidermal growth factor type II receptor) has been identified in a number of studies as a poor prognostic sign for type II endometrial carcinomas. (See",
"      <a class=\"local\" href=\"#H27282012\">",
"       'HER2 amplification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/2\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/3\">",
"      Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/4\">",
"      Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010; 21:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/5\">",
"      Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011; 54:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/6\">",
"      Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/7\">",
"      Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/8\">",
"      Zheng W, Schwartz PE. Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol 2005; 96:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/9\">",
"      Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998; 90:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/10\">",
"      Zheng W, Liang SX, Yu H, et al. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004; 12:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/11\">",
"      Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol 2006; 30:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/12\">",
"      Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/13\">",
"      Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981; 105:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/14\">",
"      Yamawaki T, Teshima H, Takeshima N, et al. [A clinicopathological study in clear cell adenocarcinoma of the endometrium]. Nihon Sanka Fujinka Gakkai Zasshi 1996; 48:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/15\">",
"      Kurman RJ, Scully RE. Clear cell carcinoma of the endometrium: an analysis of 21 cases. Cancer 1976; 37:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/16\">",
"      Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005; 11:6422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/17\">",
"      Elit L, Kwon J, Bentley J, et al. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol 2004; 92:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/18\">",
"      Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998; 69:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/19\">",
"      Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003; 91:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/20\">",
"      Kelly MG, O'malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/21\">",
"      Roelofsen T, van Ham MA, Wiersma van Tilburg JM, et al. Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol 2012; 120:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/22\">",
"      Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982; 49:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/23\">",
"      Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003; 55:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/24\">",
"      Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000; 77:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/25\">",
"      Abeler VM, Vergote IB, Kj&oslash;rstad KE, Trop&eacute; CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996; 78:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/26\">",
"      Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995; 14:30.",
"     </a>",
"    </li>",
"    <li>",
"     Goff BA. Surgical treatment of unusual endometrial cancer. In: American Society of Clinical Oncology Educational Book, 40th Annual Meeting, 2004. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/28\">",
"      Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994; 54:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/29\">",
"      Boruta DM 2nd, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004; 101:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/30\">",
"      Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/31\">",
"      Lavie O, Hornreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004; 92:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/32\">",
"      Biron-Shental T, Drucker L, Altaras M, et al. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 2006; 32:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/33\">",
"      Podratz KC, Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol Oncol 2003; 91:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/34\">",
"      Thomas M, Mariani A, Wright JD, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol 2008; 108:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/35\">",
"      Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009; 115:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/36\">",
"      Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006; 101:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/37\">",
"      Bj&oslash;rge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 2007; 120:378.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/corp.html (Accessed on August 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/39\">",
"      McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008; 17:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/40\">",
"      Wilson TO, Podratz KC, Gaffey TA, et al. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990; 162:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/41\">",
"      Abeler VM, Kj&oslash;rstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol 1991; 40:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/42\">",
"      Wright JD, Fiorelli J, Schiff PB, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 2009; 115:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/43\">",
"      Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 2003; 98:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/44\">",
"      Maxwell GL, Tian C, Risinger J, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 2006; 107:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/45\">",
"      Gehrig PA, Bae-Jump VL, Boggess JF, et al. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol 2004; 94:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/46\">",
"      Liang SX, Pearl M, Liang S, et al. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer 2011; 128:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/47\">",
"      Gupta D, Gunter MJ, Yang K, et al. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. Int J Gynecol Cancer 2011; 21:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/48\">",
"      Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, et al. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol 2008; 110:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/49\">",
"      Huang GS, Gebb JS, Einstein MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol 2007; 196:243.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/50\">",
"      Thomas MB, Mariani A, Cliby WA, et al. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol 2007; 107:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/51\">",
"      Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/52\">",
"      Moller KA, Gehrig PA, Van Le L, et al. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 2004; 94:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/53\">",
"      Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2005; 97:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/54\">",
"      Marchetti M, Vasile C, Chiarelli S. Endometrial cancer: asymptomatic endometrial findings. Characteristics of postmenopausal endometrial cancer. Eur J Gynaecol Oncol 2005; 26:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/55\">",
"      Patsavas K, Woessner J, Gielda B, et al. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol 2011; 121:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/56\">",
"      Rauh-Hain JA, Growdon WB, Schorge JO, et al. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol 2010; 119:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/57\">",
"      Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 1999; 74:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/58\">",
"      Huh WK, Powell M, Leath CA 3rd, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003; 91:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/59\">",
"      Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/60\">",
"      Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006; 94:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/61\">",
"      McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 106:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/62\">",
"      Santin AD, Bellone S, Van Stedum S, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005; 104:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/63\">",
"      Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999; 18:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/64\">",
"      Peir&oacute; G, Mayr D, Hillemanns P, et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 2004; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/65\">",
"      Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004; 22:3126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/66\">",
"      Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992; 47:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22584/abstract/67\">",
"      Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53:84.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3180 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22584=[""].join("\n");
var outline_f22_3_22584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4548929\">",
"      HISTOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1962297\">",
"      Precursor lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1962304\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1962442\">",
"      Biologic behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1962449\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4548904\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2028614\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2028723\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2028622\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STAGING AND SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2028630\">",
"      ADJUVANT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27281460\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27282012\">",
"      HER2 amplification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H119718345\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3180|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/26/15788\" title=\"table 1\">",
"      LN metastases in endometrial CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43549\" title=\"table 2\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/56/6028\" title=\"table 3\">",
"      Uterine cancer survival histol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=related_link\">",
"      Adjuvant treatment of high-risk endometrial cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=related_link\">",
"      Approach to adjuvant treatment of endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36983?source=related_link\">",
"      Endometrial carcinoma: Histopathology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_3_22585="Erythematous nodule";
var content_f22_3_22585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67641%7EID%2F68101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67641%7EID%2F68101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    A tender, erythematous nodule on the patient's middle finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &copy;2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple monomorphic, dome-shaped papules and nodules that appeared on the head and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &copy;2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22585=[""].join("\n");
var outline_f22_3_22585=null;
var title_f22_3_22586="Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy";
var content_f22_3_22586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22586/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22586/contributors\">",
"     Perry M Elliott, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22586/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22586/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22586/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22586/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/3/22586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/3/22586/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/3/22586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic disease of the cardiac sarcomere, caused by mutations in one of several genes, most of which encode components of the contractile apparatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array of clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    ). Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM are prone to both atrial and ventricular arrhythmias, the incidence of which increases with age (",
"    <a class=\"graphic graphic_figure graphicRef56594 \" href=\"UTD.htm?27/46/28397\">",
"     figure 2",
"    </a>",
"    ). Many of these arrhythmias are asymptomatic, but some can precipitate hemodynamic collapse and sudden cardiac death (SCD). SCD is a catastrophic and unpredictable complication of HCM and in some patients may be the first presentation of the disease. Thus, the evaluation of arrhythmias and their clinical consequences is one of the primary aims of the management of patients with HCM.",
"   </p>",
"   <p>",
"    The evaluation and management of ventricular arrhythmias and sudden cardiac death in patients with HCM will be reviewed here. Other issues related to ventricular arrhythmias and sudden cardiac death, as well as other clinical manifestations, natural history, diagnosis and evaluation, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the risk of SCD associated with exercise in HCM patients, activity restriction is an important component of patient management. Activity restriction in patients with HCM is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     END-STAGE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion focuses largely on those patients with the classic manifestations of HCM, including left ventricular hypertrophy, outflow obstruction, and normal left ventricular systolic function. However, there is a small subgroup of HCM patients (approximately 5 percent), who develop systolic dysfunction with left ventricular wall thinning and chamber dilation. This is often referred to as end-stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H5#H5\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'End-stage HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    End-stage HCM has a distinct pathophysiology, and management strategies are significantly different, compared to standard HCM. In general terms, these patients are managed similarly to patients with dilated cardiomyopathy (eg, with ACE inhibitors, beta blockers, and diuretics), and many such patients go on to cardiac transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link&amp;anchor=H18#H18\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\", section on 'End-stage disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to the management of arrhythmias, patients with end-stage HCM are at a high-risk of SCD and are often treated with an implantable cardioverter-defibrillator. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'ICD indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VENTRICULAR ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias are common in patients with HCM, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular premature beats (VPBs)",
"     </li>",
"     <li>",
"      Nonsustained ventricular tachycardia (NSVT)",
"     </li>",
"     <li>",
"      Ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death (SCD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency with which these arrhythmias occur was illustrated in a community-based study of 178 patients with HCM who underwent ambulatory Holter monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/1\">",
"     1",
"    </a>",
"    ]. During 24 hours of ambulatory ECG monitoring, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VPBs were present in 88 percent; 12 percent had &ge;500 VPBs and 42 percent had couplets",
"     </li>",
"     <li>",
"      NSVT was present in 31 percent and was associated with greater degrees of left ventricular hypertrophy and New York Heart Association (NYHA) class III or IV symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over 5.5 years of follow-up, the annual incidence of SCD in the entire cohort was 1.1 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors predispose to ventricular tachyarrhythmias in HCM. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocardial hypertrophy",
"     </li>",
"     <li>",
"      Myocyte disarray (",
"      <a class=\"graphic graphic_picture graphicRef55914 \" href=\"UTD.htm?11/5/11352\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myocardial fibrosis (scarring)",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Autonomic disturbance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been postulated that myocardial fibrosis is an important component of the arrhythmic substrate of HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/2\">",
"     2",
"    </a>",
"    ]. This hypothesis is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) imaging is a common finding in HCM and appears to reflect fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 53 HCM patients, hyperenhancement was present in 79 percent, and the extent of hyperenhancement correlated with the presence of two or more risk factors for SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LGE is associated with increased frequency of ventricular premature contractions and nonsustained ventricular tachycardia on Holter monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, LGE is common in HCM patients, may not reflect true myocardial scar, and is associated with SCD risk factors. The independent prognostic impact of hyperenhancement is currently the subject of investigation. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Possible risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ventricular premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats are relatively common in patients with HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. In a study cited above of 178 patients who underwent ambulatory Holter monitoring, VPBs were present in 88 percent; 12 percent had &ge;500",
"    <span class=\"nowrap\">",
"     VPBs/day",
"    </span>",
"    and 42 percent had couplets [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is no evidence to suggest that frequent VPBs are, by themselves, indicative of an increased risk of sustained ventricular arrhythmia. This is similar to other forms of heart disease in which treatment of VPBs alone is warranted only in symptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonsustained VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using ambulatory electrocardiographic monitoring have shown that approximately 15 to 31 percent of patients with HCM have runs of nonsustained VT (NSVT), which are usually asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/1,7-14\">",
"     1,7-14",
"    </a>",
"    ]. NSVT is more likely in patients with greater degrees of left ventricular hypertrophy and New York Heart Association class III or IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The prevalence of NSVT varies with age, being higher in older patients, but of greater predictive value for sudden cardiac death in the young. Episodes are most frequent during sleep and other periods of heightened vagal tone.",
"   </p>",
"   <p>",
"    NSVT confers an increased risk for SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/8-10,14\">",
"     8-10,14",
"    </a>",
"    ]. It has been suggested and it is logical to believe that risk is greater in patients with episodes of NSVT that are prolonged, repetitive, or associated with symptoms of impaired consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This hypothesis was tested in a series of 531 HCM patients, 104 of whom had NSVT. The presence of NSVT was associated with an increased risk of sudden death, particularly in younger patients. The odds ratio of sudden death in patients &le;30 years of age with NSVT was 4.35 (95% CI 1.54-12.28) compared with 2.16 (95% CI 0.82 to 5.69) in those aged &gt;30. There was, however, no relation among duration, frequency, or rate of NSVT episodes and prognosis at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'High-risk clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sustained VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically documented sustained VT is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/15\">",
"     15",
"    </a>",
"    ]. Spontaneous sustained VT can present with palpitations, presyncope, or occasionally syncope. A number of case reports suggest that sustained VT is occasionally associated with apical left ventricular aneurysms in patients with long-standing mid-cavity obliteration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/16-18\">",
"     16-18",
"    </a>",
"    ] while ICD recordings reveal that monomorphic, as well as polymorphic, VT are the usual antecedent rhythms in patients who develop VF [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Medical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that pharmacologic therapy reduces the risk of malignant arrhythmias in HCM patients. Thus, such treatment is not indicated for low-risk asymptomatic patients.",
"   </p>",
"   <p>",
"    Medical therapy may be considered in selected patients for the purpose of reducing symptoms associated with arrhythmias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as an adjunct in patients with an ICD. Our general approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic VPBs do not require therapy, but beta blockers may be effective in symptomatic patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"       \"Clinical significance and treatment of ventricular premature beats\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asymptomatic NSVT is not treated with antiarrhythmic drugs. However, because NSVT is associated with an increased risk of SCD, its presence should be taken into account when considering an individual's risk for SCD and the need for ICD therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Identifying high-risk patients'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with symptomatic NSVT can be treated with beta blockers, or in selected patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The purpose of such therapy is symptom control. In patients felt to be at high-risk for SCD, neither drug is an adequate alternative to an ICD. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Prevention of SCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained VT in the absence of an identifiable provoking factor is generally regarded as a major risk factor for SCD. Nearly all such patients receive an ICD for secondary prevention. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prevention of SCD'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with frequent arrhythmia recurrences who experience multiple shocks, the first option is usually adjunctive antiarrhythmic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/21\">",
"     21",
"    </a>",
"    ]. In case reports of incessant ventricular arrhythmias, both radiofrequency ablation and surgical resection of an LV aneurysm have been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/17,22\">",
"     17,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUDDEN CARDIAC DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death (SCD) is the most feared complication of hypertrophic cardiomyopathy (HCM). With the availability of effective prophylactic treatment, ie the implantable cardioverter-defibrillator (ICD), the identification of patients at an increased risk of SCD has acquired greater clinical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of SCD across the entire spectrum of HCM patients is approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/1,23-26\">",
"     1,23-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Identifying high-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HCM have an increased risk of death from several causes (SCD, heart failure, and stroke). The following discussion will review the risk factors associated with SCD in HCM patients. These and other risk factors have also been evaluated for their more general association with overall mortality and outcomes. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H9#H9\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk stratification for SCD should be performed in all patients with HCM, regardless of their symptomatic or hemodynamic status or the apparent morphological severity of disease. Several society guidelines for HCM as well as ventricular arrhythmias and sudden cardiac death have outlined the risk factors for SCD in patients with HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10,26-30\">",
"     10,26-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prior arrhythmic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first two major risk factors are actually prior ventricular arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior cardiac arrest",
"     </li>",
"     <li>",
"      Spontaneous sustained VT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HCM patients who survive a cardiac arrest due to VT or ventricular fibrillation (VF) are at an increased risk for recurrent events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/19,31-33\">",
"     19,31-33",
"    </a>",
"    ]. This risk was illustrated in a series of 33 patients successfully resuscitated from a cardiac arrest prior to the widespread use of ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/31\">",
"     31",
"    </a>",
"    ]. They were treated with a variety of strategies, including septal myotomy and medical therapy. Despite treatment, recurrent arrhythmias were common. The survival rates free of recurrent cardiac arrest or death after one, five, and ten years were 83, 65, and 53 percent, respectively.",
"   </p>",
"   <p>",
"    A high rate of recurrent ventricular arrhythmias in HCM patients with a history of cardiac arrest or sustained VT is further supported by the frequency of appropriate shocks in patients who received an ICD for secondary prevention of SCD. In two series of 13 and 43 such patients, the incidence of appropriate shocks was 6.3 and 11 percent per year, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/19,33\">",
"     19,33",
"    </a>",
"    ]. Although higher incidences of appropriate shocks have been reported in other patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/33\">",
"     33",
"    </a>",
"    ], this event rate in a younger cohort than ICD recipients with coronary artery disease justifies the placement of an ICD for secondary prevention of SCD in HCM patients who survive a cardiac arrest or episode of sustained VT. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Prevention of SCD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     High-risk clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because many patients do not survive their first ventricular arrhythmic event, it is more useful to define features that identify patients at high-risk of arrhythmias before they occur. Additional major risk factors listed in the 2011",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    guidelines on HCM are examples of such features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/30\">",
"     30",
"    </a>",
"    ]. They are similar to those described in a number of HCM reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major risk factors have limited sensitivity and moderate to high specificity for predicting SCD (",
"    <a class=\"graphic graphic_table graphicRef80617 \" href=\"UTD.htm?13/5/13405\">",
"     table 2",
"    </a>",
"    ). However, evaluation for major risk factors helps to identify patients in whom an ICD is warranted for primary prevention. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'ICD indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The five major risk factors that are most commonly cited are the following (",
"    <a class=\"graphic graphic_table graphicRef74083 \" href=\"UTD.htm?36/53/37724\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family history of SCD &mdash; A family history of HCM-related SCD is associated with an increased risk of sudden death in other affected family members [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. This risk is particularly high if there are multiple SCD events in one family, and if the events occur in younger patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. In a report of 41 relatives from eight such families, 31 (75 percent) died from their heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/35\">",
"       35",
"      </a>",
"      ]. Among these 31 patients, 18 died before age 25, 23 of the deaths were sudden, and, in 15 of these 23 patients, SCD was the initial manifestation of the disease. Families with multiple sudden deaths under the age of 40, however, are uncommon (approximately 5 percent), whereas a single sudden death is seen in up to 25 percent of families [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10,36\">",
"       10,36",
"      </a>",
"      ], but is of low positive predictive accuracy (&lt;15 percent).",
"     </li>",
"     <li>",
"      Syncope &mdash; Syncope, if it is not clearly attributable to another cause (eg, neurocardiogenic syncope or paroxysmal atrial fibrillation), is a risk factor for SCD in patients with HCM [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10,37\">",
"       10,37",
"      </a>",
"      ]. The risk is greatest if syncope is repetitive, associated with exertion, or occurs in children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/37\">",
"       37",
"      </a>",
"      ]. Exercise-related obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mitral regurgitation should be excluded in those with exertional syncope. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSVT &mdash; Asymptomatic NSVT (defined as &ge;3 beats at 120 beats per minute) confers increased risk for SCD in patients with HCM [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/8,9,11,13,14,38\">",
"       8,9,11,13,14,38",
"      </a>",
"      ]. The magnitude of this effect was illustrated in a study of 99 HCM patients who underwent 24-hour ambulatory monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/9\">",
"       9",
"      </a>",
"      ]. 19 had asymptomatic NSVT, and the presence of NSVT identified a high-risk group in which the incidence of SCD was 8.6 percent per year compared to 1 percent per year in the patients without any ventricular arrhythmia or frequent VPBs. A European study of the same year, which also included children and adolescents, showed very similar results [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/8\">",
"       8",
"      </a>",
"      ]. Another study of 178 HCM adults aged 20 to 50 years, revealed a 31 percent prevalence of NSVT and an overall annual sudden death rate of 1.1 percent. In this cohort of older patients, there was a smaller increase in risk with NSVT (1.6 versus 0.9 percent per year in patients with and without NSVT defined as &ge;3 beats at 100 beats per minute) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The increase in risk with NSVT is greatest in the young and those with symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/1,11,13,14,24,25\">",
"       1,11,13,14,24,25",
"      </a>",
"      ]. In a study of 531 patients with HCM, 104 had NSVT; 32 died suddenly during mean follow-up of 70 months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/14\">",
"       14",
"      </a>",
"      ]. The odds ratio of sudden death in patients &le;30 with NSVT was 4.35 (95% CI 1.54-12.28, p = 0.006) compared with 2.16 (95% CI 0.82-5.69, p = 0.1) in those aged &gt;30. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonsustained VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal BP response to exercise &mdash; Exercise testing is an important part of the evaluation of the HCM patient. It provides objective data on exercise capacity, ischemia, and blood pressure response, which guide management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Exercise testing'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Between 20 and 40 percent of patients with HCM fail to augment their baseline blood pressure during exercise. In some of these patients, the blood pressure falls below baseline values during or immediately following exercise. This abnormal blood pressure response during a maximal symptom-limited upright exercise test is associated with an increased risk for SCD, in patients younger than 40 years of age and those with a family history of premature SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10,39,40\">",
"       10,39,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The finding of an abnormal BP response to exercise and its significance with regard to SCD risk is distinct from the finding and implications of markers of ischemia (eg, ECG changes, perfusion defects) that may occur with stress testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H9#H9\">",
"       \"Natural history of hypertrophic cardiomyopathy\", section on 'Mortality'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Exercise testing'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Development of a substantial left ventricular outflow gradient during exercise may explain the abnormal blood pressure response in a minority of patients. Similar blood pressure responses occur in patients with nonobstructive disease that seems to be related to inappropriate vasodilatation in nonexercising muscles. In addition, this abnormal blood pressure response is often associated with a relative bradycardia, suggesting activation of the Bezold-Jarisch reflex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'BP response'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link&amp;anchor=H5#H5\">",
"       \"Reflex syncope\", section on 'Autonomic dysfunction'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The predictive value of an abnormal blood pressure response was evaluated in a series of 161 consecutive patients with HCM who were &le;40 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/39\">",
"       39",
"      </a>",
"      ]. A normal blood pressure response was defined as a gradual increase in systolic pressure from rest to peak exercise of &ge;20 mmHg, with a gradual decline during recovery. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An abnormal BP response was noted in 60 patients (37 percent). Two types of abnormal responses were noted: an increase in the systolic pressure of &lt;20 mmHg from rest to peak exercise; or, during exercise, a decrease in systolic pressure of more than 20 mmHg from the peak value.",
"     </li>",
"     <li>",
"      At a mean follow-up of 44 months, the rate of SCD was significantly higher in patients with an abnormal response (15 versus 3 percent in those with a normal response).",
"      <br/>",
"      <br/>",
"      An abnormal BP response to upright exercise is a sensitive but non-specific marker of sudden death risk in the young.",
"      <br/>",
"      <br/>",
"      If abnormal BP response to exercise is normalized by myectomy or septal ablation, it is reasonable to consider this risk factor eliminated although evidence to support this approach is lacking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Massive left ventricular hypertrophy &mdash; A left ventricular (LV) wall thickness &ge;30 mm is seen in approximately 10 percent of patient cohorts and is associated with an increased risk of SCD, particularly in patients less than 30 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/41-43\">",
"       41-43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The relation of massive LVH and sudden death was highlighted by a study of 480 patients who were followed for a mean of 6.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/41\">",
"       41",
"      </a>",
"      ]. The risk of SCD was zero for a wall thickness &le;15 mm compared to 1.8 percent per year for a wall thickness &ge;30 mm; the incidence of SCD almost doubled for each 5 mm increase in wall thickness (",
"      <a class=\"graphic graphic_figure graphicRef75913 \" href=\"UTD.htm?36/46/37613\">",
"       figure 3",
"      </a>",
"      ). The cumulative risk 20 years after the initial diagnosis was close to 0 for those with a thickness &le;19 mm compared to 40 percent for a wall thickness &ge;30 mm.",
"      <br/>",
"      <br/>",
"      The presence of massive LVH warrants careful evaluation for risk markers of hemodynamic and electrical instability. If the accuracy of wall thickness measurements is confirmed, an ICD should be considered, particularly in young patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, not all series have confirmed the association between massive LVH and SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/44\">",
"       44",
"      </a>",
"      ], and the positive predictive value is low [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. Thus, as with the other major risk factors, massive LVH is most useful if considered within the context of the overall risk profile.",
"      <br/>",
"      <br/>",
"      A study of 630 patients followed for a mean of five years illustrated the value of considering massive LVH in conjunction with additional risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/42\">",
"       42",
"      </a>",
"      ]. This study revealed that the number of additional risk factors (ie, family history of sudden death, syncope, NSVT, abnormal BP response) was a better predictor of risk of sudden death than LV wall thickness (p = 0.0001, relative risk per additional risk factor 2.00 versus p = 0.058, 1.26 per 5 mm increment).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Possible risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other factors contribute to the overall SCD risk profile.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age at diagnosis &mdash; There is an annual incidence of SCD of up to 6 percent when HCM is diagnosed in childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/34\">",
"       34",
"      </a>",
"      ]. It has been suggested, but not proven, that older age may confer less risk for SCD because survival to that age implies more benign disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Conversely, the presence of the major risk factors, unexplained syncope, NSVT, an abnormal blood pressure response, and massive LVH are of greater prognostic significance in children and adolescents. The impact of age at diagnosis on overall mortality risk (ie, in addition to SCD) is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H9#H9\">",
"       \"Natural history of hypertrophic cardiomyopathy\", section on 'Mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LV outflow gradient &mdash; Most natural history studies from the 1970s, '80s and '90s failed to show an association of LVOT gradient and adverse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/24,25,34,46,47\">",
"       24,25,34,46,47",
"      </a>",
"      ]. Two recent large studies, however, have shown a weak association of LVOT gradients with overall disease-related mortality and sudden death [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. The impact of LVOT obstruction on overall mortality risk (ie, in addition to SCD) is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H9#H9\">",
"       \"Natural history of hypertrophic cardiomyopathy\", section on 'Mortality'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Eleven hundred and one HCM patients from two Italian and one American center were followed for a mean of six years. The probability of HCM-related death and of sudden death was slightly greater in those with LVOT gradient of at least 30 mmHg (relative risk approximately 2.0 for each) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/49\">",
"       49",
"      </a>",
"      ]. The magnitude of the gradient, however, was not associated with significant increased risk of either sudden death or disease-related mortality. The authors felt that the relationship between gradient and sudden death was not sufficiently strong for obstruction to be considered a substantial determinant of decisions to implant ICDs prophylactically [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/49\">",
"       49",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The possible influence of obstruction on outcome was assessed in a single UK center in 917 HCM patients, 31 percent of whom had an LV outflow tract gradient &ge;30 mmHg at rest [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/48\">",
"       48",
"      </a>",
"      ]. At a median follow-up of 61 months, survival from all cause",
"      <span class=\"nowrap\">",
"       mortality/transplant",
"      </span>",
"      was lower in patients with obstruction (86.5 versus 90.1 percent), as was survival from sudden",
"      <span class=\"nowrap\">",
"       death/ICD",
"      </span>",
"      discharge (91.4 versus 95.7 percent). Outflow obstruction was independently associated with SCD (RR = 2.4) and there was a significant trend towards lower sudden",
"      <span class=\"nowrap\">",
"       death/ICD",
"      </span>",
"      survival in patients with increasing outflow obstruction. On multivariate analysis, severe LVOT obstruction (&ge;90 mmHg) was a predictor of sudden death (RR 3.82).",
"      <br/>",
"      <br/>",
"      The incidence of SCD in patients with obstruction also varied substantially based upon the number of additional risk factors (",
"      <a class=\"graphic graphic_figure graphicRef65115 \" href=\"UTD.htm?16/27/16831\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/48\">",
"       48",
"      </a>",
"      ]. For patients with an outflow gradient &ge;30 mmHg, but no additional risk factors, the annual incidence of SCD or ICD discharge was low. The low sudden death rates in asymptomatic patients with LVOT obstruction and those with no other risk markers suggests that prophylactic ICD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       myectomy/alcohol",
"      </span>",
"      ablation to reduce gradients are unwarranted in this group. The higher risk in those with severe obstruction supports strategies for gradient reduction in those with symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/50\">",
"       50",
"      </a>",
"      ]. However, for patients with severe gradients who are asymptomatic, there is no role for myectomy or alcohol ablation. The authors concluded that in the absence of other risk factors, LVOT obstruction was not of sufficient predictive power to warrant a prophylactic ICD. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonpharmacologic treatment of LVOT obstruction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Diastolic dysfunction &mdash; Diastolic dysfunction may be a risk factor for death or sustained VT, at least in children. This was suggested in a study of 80 consecutive patients ages one to 18 (median 12 years) evaluated with two dimensional and Doppler echocardiography as well as tissue Doppler imaging and followed for a median of 26 months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/51\">",
"       51",
"      </a>",
"      ]. The combined end point of cardiac death, cardiac arrest, or sustained VT occurred in 14 (18 percent). The ratio of mitral inflow velocity to mitral annular velocity",
"      <span class=\"nowrap\">",
"       (E/Ea,",
"      </span>",
"      a noninvasive estimate of left ventricular filling pressure) was significantly higher among patients who met the primary end point than among those who did not (13.7 versus 8.5). The",
"      <span class=\"nowrap\">",
"       E/Ea",
"      </span>",
"      ratio remained a significant predictor after correction for other variables including maximal left ventricular wall thickness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link\">",
"       \"Tissue Doppler echocardiography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocardial ischemia &mdash; There are conflicting data as to whether myocardial ischemia is a risk factor for SCD in HCM patients. The relationship between ischemic and outcomes is likely dependent upon both the age of the patient and the etiology of ischemia (eg, myocardial bridging versus coronary artery disease). The impact of stress induced ischemia on overall mortality risk (ie, in addition to SCD) is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H9#H9\">",
"       \"Natural history of hypertrophic cardiomyopathy\", section on 'Mortality'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In a series of 23 young patients with HCM (age 6 to 23 years), ischemia was associated with a history of cardiac arrest or syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/52\">",
"       52",
"      </a>",
"      ]. In contrast, there was no relation between the presence of ischemia and outcomes in a larger, prospective series of 216 unselected HCM patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is conflicting evidence as to whether myocardial bridging increases the risk of SCD. In a series of 36 children with HCM, myocardial bridging was detected by angiography in ten, and was associated with a marked increase in subsequent cardiac arrest (50 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/54\">",
"       54",
"      </a>",
"      ]. However, other reports in both children and adults found no association between myocardial bridging and sudden death [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/47/12023?source=see_link\">",
"       \"Myocardial bridging of the coronary arteries\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast, HCM patients with coincident coronary artery disease have mortality rates that exceed those of CAD patients with normal left ventricular function [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Late gadolinium enhancement on cardiovascular magnetic resonance imaging&mdash; Late gadolinium myocardial enhancement (LGE) on cardiovascular magnetic resonance (CMR) imaging is common in HCM and appears to reflect fibrosis which has been proposed as a potential pathogenic factor for arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The extent of LGE is greater in patients with two or more high-risk clinical features for SCD in HCM [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/4\">",
"       4",
"      </a>",
"      ]. LGE is associated with increased frequency of ventricular premature contractions and nonsustained ventricular tachycardia on Holter monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genotype &mdash; There appear to be high-risk genotypes for SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/59\">",
"       59",
"      </a>",
"      ], particularly related to troponin T disease and several of the beta myosin heavy chain mutations. However, the available data is derived from a small number of families and may be skewed on this basis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/28,30\">",
"       28,30",
"      </a>",
"      ]. Moreover, most mutations are novel and thus a certain genotype may have been specific or sensitive marker in a particular family but would not be so in the general population. In addition, it appears that with the exception of troponin T mutation carriers, genetically affected but phenotypically normal individuals are not at increased risk of SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"       \"Genetics of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Impact of number of risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of high-risk patients may be improved by using multiple factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10,48\">",
"     10,48",
"    </a>",
"    ]. This was addressed in a study of 368 patients, mean age 37 years, who were followed for a mean of 3.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10\">",
"     10",
"    </a>",
"    ]. The estimated six year SCD-free survival was associated with the number of risk factors, which were the same as those noted above (",
"    <a class=\"graphic graphic_figure graphicRef75731 \" href=\"UTD.htm?37/63/38909\">",
"     figure 5",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H13\">",
"     'High-risk clinical features'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zero (55 percent of the cohort) &mdash; 95 percent",
"     </li>",
"     <li>",
"      One (33 percent of the cohort) &mdash; 93 percent",
"     </li>",
"     <li>",
"      Two or three risk factors (12 percent of the cohort) &mdash; 72 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with two or three risk factors had a SCD rate of 4.7 percent per year, which is similar to the 5 percent per year rate in high-risk patients in an ICD study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/19\">",
"     19",
"    </a>",
"    ]. The use of multiple risk factors is generally in agreement with recommendations from professional societies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/30,37\">",
"     30,37",
"    </a>",
"    ]. These organizations recommend that HCM patients with two or more of the five major risk factors should receive an ICD for primary prevention of SCD.",
"   </p>",
"   <p>",
"    On the other hand, data from a multicenter registry of ICDs in patients with HCM are presented, suggesting that a single risk factor may be sufficient justification for consideration of ICD implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/60\">",
"     60",
"    </a>",
"    ]. Of the 383 patients in the primary prevention group, 18 of the 51 patients with appropriate ICD interventions had undergone implantation for only a single risk factor. Likelihood of appropriate discharge was similar in patients with 1, 2, or 3 or more risk factors (3.83, 2.65, and 4.82 per 100 person-years). A limitation to interpretation of this study is that risk assessment was retrospective and did not include exercise testing and, in addition, Holter data was missing in approximately 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Low risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with no risk factors had a 5 percent SCD risk at six years (0.83 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10\">",
"     10",
"    </a>",
"    ]. Four of the six patients who died without risk factors had significant co-existent coronary artery disease or severe obstruction. The authors conclude that patients with none of the major risk factors are at a low risk of SCD, particularly if other aspects of their clinical profile are similarly benign [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/10,28,61\">",
"     10,28,61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'High-risk clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Data in these patients are limited, but those meeting the following profile probably have an incidence of SCD of between 0.2 and 0.4 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/28,30,61\">",
"     28,30,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      None of the five major risk factors",
"     </li>",
"     <li>",
"      No or only mild symptoms of heart failure",
"     </li>",
"     <li>",
"      Left atrium &le;45 mm",
"     </li>",
"     <li>",
"      LV wall thickness &lt;20 mm",
"     </li>",
"     <li>",
"      LV outflow gradient &lt;50 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, it appears that with the exception of troponin T mutation carriers, genetically affected but phenotypically normal individuals are not at increased risk of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical activity and SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the potential risk of SCD associated with exercise in HCM patients, activity restriction is an important component of patient management. Activity restriction in patients with HCM is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonpharmacologic treatment of LVOT obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence suggests that septal myectomy to treat symptomatic left ventricular outflow tract obstruction may reduce the risk of SCD and the rate of appropriate ICD discharges [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/50,62\">",
"     50,62",
"    </a>",
"    ]. In contrast, septal ablation has not been demonstrated to reduce SCD or ICD discharge rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential importance of LVOT gradient immediately following alcohol septal ablation (ASA) was suggested by a preliminary report [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/63\">",
"     63",
"    </a>",
"    ]. Among 42 HCM patients with an ICD or permanent pacemaker who underwent ASA, a greater rate of arrhythmic events",
"    <span class=\"nowrap\">",
"     (VT/VF,",
"    </span>",
"    cardiac arrest, or appropriate ICD therapy) was observed among patients with a higher LVOT gradient immediately post-ASA (hazard ratio 2.7 per 10 mmHg gradient, 95% CI 1.6 to 4.6).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation and serial monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the dynamic nature of the disease, all patients with HCM should undergo serial evaluations that include a reassessment for risk of complications. Annual evaluations should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History and physical examination",
"     </li>",
"     <li>",
"      Interim family history",
"     </li>",
"     <li>",
"      Echocardiography",
"     </li>",
"     <li>",
"      24 to 48 hour ambulatory monitoring",
"     </li>",
"     <li>",
"      Exercise testing to assess blood pressure response",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a patient who has an ICD, tests for the purpose of risk stratification (eg, ambulatory monitoring for NSVT) are not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     EP testing and ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some observational studies suggested that electrophysiology (EP) testing may be useful, it has not been shown to be a reliable predictor of SCD in HCM patients.",
"   </p>",
"   <p>",
"    The electrophysiologic properties of the hypertrophied septum in some HCM patients include abnormalities associated with myocardial scar, such as reduced voltage and conduction delay [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/64\">",
"     64",
"    </a>",
"    ]. These findings are consistent with an arrhythmic substrate. In addition, some observational data suggests that HCM patients with inducible arrhythmias are at an increased risk for SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the majority of inducible arrhythmias in HCM patients are nonsustained or polymorphic, which are not specific predictors of arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/11,65\">",
"     11,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In selected cases of patients with incessant VT, radiofrequency catheter ablation has been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antiarrhythmic drugs is limited to adjunctive therapy in patients with an ICD who experience frequent arrhythmias, or as an alternative to an ICD in high-risk patients who are not candidates for or choose not to have an ICD, usually due to substantial comorbidities. Observational data suggests that pharmacologic therapy has little impact on the incidence of SCA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/66\">",
"     66",
"    </a>",
"    ]. When antiarrhythmic drugs are used in this setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is preferred, although data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/20,21,29\">",
"     20,21,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines for ventricular arrhythmias and sudden cardiac death include the recommendation that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy can be effective for treatment in patients with HCM with a history of sustained VT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    VF when an ICD is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     ICD prevention of SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICD is the preferred therapy for HCM patients at high-risk of SCD. Randomized trials have not been performed; as a result, the indications for an ICD are derived from observational data that define high-risk populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     ICD indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for both primary and secondary prevention of SCD with an ICD have been made by the multiple professional societies (",
"    <a class=\"graphic graphic_table graphicRef58573 \" href=\"UTD.htm?10/3/10300\">",
"     table 4",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/29,30,37,67\">",
"     29,30,37,67",
"    </a>",
"    ]. These recommendations are in general agreement with those of more recent expert reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. All of these recommendations are based upon non-randomized observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is general agreement that an ICD is effective for secondary prevention in survivors of cardiac arrest or sustained spontaneous VT who have \"reasonable expectation of survival with a good functional status for more than one year\" [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For primary prevention, the weight of evidence supports use of an ICD in high-risk patients. High-risk patients are generally defined as those who have one or more of the five major risk factors outlined above. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'High-risk clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important subset of patients with a single risk factor will also be at increased risk from sudden death. The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death note that an ICD is reasonable in patients with one or more major risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/67\">",
"     67",
"    </a>",
"    ].(See",
"    <a class=\"local\" href=\"#H15\">",
"     'Impact of number of risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Possible risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with end-stage HCM, characterized by LV systolic dysfunction and LV wall thinning and chamber dilation, are at high-risk for SCD and are also candidates for ICD therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'End-stage disease'",
"      </a>",
"      above.) Such patients may qualify for ICD implantation on the basis of SCD-HeFT criteria (LV ejection fraction &le;35 percent and NYHA class II or III heart failure). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H29#H29\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'ICD therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, because of the additional increased risk of SCD in HCM patients, we recommend ICD implantation in end-stage HCM patients even if they fall outside of the SCD-HeFT criteria. Furthermore, patients with end-stage HCM may have NYHA class IV HF, which would also put them outside of SCD-HeFT criteria. If such a patient is being considered for cardiac transplantation, ICD implantation is reasonable as a bridge to transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     ICD efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials to provide evidence of improved survival with an ICD in HCM patients. However, support for the efficacy of ICDs in HCM comes from the known rate of SCD in high-risk patients and from the incidence of appropriate ICD therapies in patients who have had one implanted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/32,60,68\">",
"     32,60,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of ICD therapies was illustrated by a report of 506 HCM patients from a multicenter registry [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/60\">",
"     60",
"    </a>",
"    ]. Twenty-four percent of patients had ICD implantation for secondary prevention. The remaining patients had implantation for primary prevention due to the presence of one or more of the following four high-risk features: (1) family history of premature HCM-related sudden death, (2) massive left ventricular hypertrophy, (3) NSVT on Holter monitoring, and (4) prior unexplained syncope. At an average follow-up of 3.7 years, 20 percent of patients received appropriate ICD interventions including 7 percent who also received inappropriate ICD shocks. Twenty percent of patients received only inappropriate ICD shocks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H17#H17\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Inappropriate shocks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of appropriate device activation was 10.6 percent per year when used for secondary prevention of SCD and 3.6 percent per year when used for primary prevention. The impact of the number of risk factors is discussed above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Impact of number of risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     BRADYARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic findings in patients with HCM include slow atrioventricular (AV) node and His-Purkinje conduction, which present clinically as first or second degree AV block [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/69\">",
"     69",
"    </a>",
"    ]. It is unclear, however, whether these abnormalities translate into a higher incidence of bradyarrhythmias or heart block. Nevertheless, bradyarrhythmias should always be considered in patients with HCM who present with syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the evaluation and management of ventricular arrhythmias in patients with HCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nonsustained ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCM patients often have ventricular premature beats (VPBs) or NSVT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with asymptomatic VPBs or NSVT, we recommend that pharmacologic therapy not be given for the purpose of arrhythmia suppression (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Medical treatment'",
"      </a>",
"      above.) However, because NSVT is associated with an increased risk of SCD, its presence should be taken into account when considering the need for ICD therapy.",
"     </li>",
"     <li>",
"      In patients with symptoms due to VPBs or NSVT, we suggest pharmacologic treatment for symptom control (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Beta blockers are the preferred initial therapy, and in refractory cases, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      . The purpose of medical therapy is the control of symptoms; it should not be considered an alternative to an ICD in patients at high-risk of SCD. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Medical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prevention of SCD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Physical activity restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity restriction in patients with HCM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     ICD use",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCD is the most feared complication of HCM. ICD implantation is the best available therapy for patients at high-risk of SCD. The following recommendations are in general agreement with the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology and the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/3/22586/abstract/29,67\">",
"     29,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who survive an episode of sustained ventricular tachycardia or SCD, we recommend implantation of an ICD for the secondary prevention of SCD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prevention of SCD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients determined to be at high-risk of SCD, with one or more major risk factors, we suggest implantation of an ICD for the primary prevention of SCD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'High-risk clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with end-stage HCM, characterized by LV systolic dysfunction, LV wall thinning and chamber dilation, we recommend implantation of an ICD for primary prevention of SCD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'ICD indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with frequent sustained ventricular arrhythmias resulting in ICD shocks should be treated with adjunctive antiarrhythmic therapy, most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or radiofrequency ablation. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Prevention of SCD'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/1\">",
"      Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/2\">",
"      Basso C, Thiene G, Corrado D, et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000; 31:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/3\">",
"      Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/4\">",
"      Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/5\">",
"      Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/6\">",
"      Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/7\">",
"      Savage DD, Seides SF, Maron BJ, et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979; 59:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/8\">",
"      McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/9\">",
"      Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981; 48:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/10\">",
"      Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/11\">",
"      Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/12\">",
"      Cecchi F, Olivotto I, Montereggi A, et al. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998; 79:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/13\">",
"      Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994; 90:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/14\">",
"      Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/15\">",
"      Shakespeare CF, Keeling PJ, Slade AK, McKenna WJ. Arrhythmia and hypertrophic cardiomyopathy. Arch Mal Coeur Vaiss 1992; 85 Spec No 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/16\">",
"      Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. Br Heart J 1989; 61:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/17\">",
"      Mantica M, Della Bella P, Arena V. Hypertrophic cardiomyopathy with apical aneurysm: a case of catheter and surgical therapy of sustained monomorphic ventricular tachycardia. Heart 1997; 77:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/18\">",
"      Abinader EG, Sharif D, Shefer A, Naschitz J. Novel insights into the natural history of apical hypertrophic cardiomyopathy during long-term follow-up. Isr Med Assoc J 2002; 4:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/19\">",
"      Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/20\">",
"      McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/21\">",
"      McKenna WJ, Harris L, Rowland E, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984; 54:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/22\">",
"      Rodriguez LM, Smeets JL, Timmermans C, et al. Radiofrequency catheter ablation of sustained monomorphic ventricular tachycardia in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 1997; 8:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/23\">",
"      Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/24\">",
"      Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/25\">",
"      Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989; 320:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/26\">",
"      Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/27\">",
"      Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006; 332:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/28\">",
"      Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/29\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/30\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:e783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/31\">",
"      Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989; 13:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/32\">",
"      Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/33\">",
"      Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998; 31:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/34\">",
"      McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/35\">",
"      Maron BJ, Lipson LC, Roberts WC, et al. \"Malignant\" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978; 41:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/36\">",
"      McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002; 87:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/37\">",
"      Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/38\">",
"      Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 32:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/39\">",
"      Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/40\">",
"      Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/41\">",
"      Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/42\">",
"      Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/43\">",
"      Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 2006; 19:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/44\">",
"      Olivotto I, Gistri R, Petrone P, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/45\">",
"      Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005; 45:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/46\">",
"      McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation 1989; 80:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/47\">",
"      Maron BJ, Bonow RO, Cannon RO 3rd, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/48\">",
"      Elliott PM, Gimeno JR, Tom&eacute; MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/49\">",
"      Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/50\">",
"      Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/51\">",
"      McMahon CJ, Nagueh SF, Pignatelli RH, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004; 109:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/52\">",
"      Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/53\">",
"      Yamada M, Elliott PM, Kaski JC, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur Heart J 1998; 19:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/54\">",
"      Yetman AT, McCrindle BW, MacDonald C, et al. Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death. N Engl J Med 1998; 339:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/55\">",
"      Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol 2000; 36:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/56\">",
"      Sorajja P, Ommen SR, Nishimura RA, et al. Myocardial bridging in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/57\">",
"      Sorajja P, Ommen SR, Nishimura RA, et al. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003; 108:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/58\">",
"      Maron BJ, Maron MS, Lesser JR, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008; 101:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/59\">",
"      Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 1999; 281:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/60\">",
"      Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/61\">",
"      Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/62\">",
"      McLeod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007; 28:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/63\">",
"      Noseworthy PA, Rosenberg MA, Fifer MA, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2009; 104:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/64\">",
"      Schumacher B, Gietzen FH, Neuser H, et al. Electrophysiological characteristics of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy and moderate to severe symptoms. Circulation 2005; 112:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/65\">",
"      Kuck KH, Kunze KP, Schl&uuml;ter M, et al. Programmed electrical stimulation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J 1988; 9:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/66\">",
"      Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007; 93:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/67\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/68\">",
"      Begley DA, Mohiddin SA, Tripodi D, et al. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/3/22586/abstract/69\">",
"      Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989; 80:1259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4952 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22586=[""].join("\n");
var outline_f22_3_22586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      END-STAGE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VENTRICULAR ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonsustained VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sustained VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUDDEN CARDIAC DEATH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Identifying high-risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prior arrhythmic events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - High-risk clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Possible risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Impact of number of risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Low risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical activity and SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonpharmacologic treatment of LVOT obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation and serial monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EP testing and ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ICD prevention of SCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - ICD indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - ICD efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      BRADYARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nonsustained ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prevention of SCD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Physical activity restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - ICD use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4952\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4952|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/46/28397\" title=\"figure 2\">",
"      Relationship between age and arrhythmias in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/46/37613\" title=\"figure 3\">",
"      Wall thickness sudden death HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/27/16831\" title=\"figure 4\">",
"      SCD and risk factors in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/63/38909\" title=\"figure 5\">",
"      Risk model SCD HCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4952|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/5/11352\" title=\"picture 1\">",
"      HCM myocyte disarray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4952|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13405\" title=\"table 2\">",
"      Markers of risk in HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/53/37724\" title=\"table 3\">",
"      ESC risk stratification HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/3/10300\" title=\"table 4\">",
"      ESC primary prevention SCD HCM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/47/12023?source=related_link\">",
"      Myocardial bridging of the coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_3_22587="Drugs which cause anemia in HIV";
var content_f22_3_22587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common drug-Related causes of anemia in HIV-infected patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antiretroviral agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidovudine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapy for opportunistic infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ganciclovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyrimethamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primaquine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dapsone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimetrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ribavirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chemotherapeutic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Interferon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunoglobulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-RhD",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22587=[""].join("\n");
var outline_f22_3_22587=null;
var title_f22_3_22588="SSx exposure to intimate partner violence";
var content_f22_3_22588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms of childhood exposure to intimate partner violence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infants and toddlers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disrupted sleep patterns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disrupted feeding routines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to thrive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive screaming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental delays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pre-schoolers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-traumatic stress symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aggressive behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regressive behaviors such as bed-wetting, thumb-sucking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nightmares",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        School-age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Problems concentrating and focusing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral problems such as conduct disorders or mood disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullying/aggressive behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor academic performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatic complaints such as chronic headache or abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance abuse problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexual promiscuity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teen pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexually transmitted infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School failure/truancy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Evans SE, Davies C, DiLillo D. Exposure to domestic violence: A meta-analysis of child and adolescent outcomes. Aggression and Violent Behavior 2008; 13:131.",
"      </li>",
"      <li>",
"       Holt S, Buckley H, Whelan S. The impact of exposure to domestic violence on children and young people: A review of the literature. Child Abuse &amp; Negl 2008; 32:797.",
"      </li>",
"      <li>",
"       Knapp JF. The impact of children witnessing violence. Pediatric Clinics of North America 1998; 45:355.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22588=[""].join("\n");
var outline_f22_3_22588=null;
var title_f22_3_22589="Causes of osteomalacia";
var content_f22_3_22589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of osteomalacia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Abnormal vitamin D metabolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            (causing secondary hyperparathyroidism and hypophosphatemia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Deficient intake or absorption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dietary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inadequate sunlight exposure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malabsorption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastrectomy or gastrointestinal bypass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Small bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pancreatic insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Defective 25-hydroxylation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Biliary cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Alcoholic cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anticonvulsants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Loss of vitamin D binding protein",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nephrotic syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Defective 1-alpha 25-hydroxylation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypoparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Renal failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vitamin D-dependent rickets type 1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Defective target organ response to calcitriol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vitamin D-dependent rickets, type II (Hereditary vitamin D resistant rickets, HVDRR)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Mineralization defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Abnormal matrix",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic renal failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Osteogenesis imperfecta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fibrogenesis imperfecta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Axial osteomalacia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Enzyme deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypophosphatasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inhibitors of mineralization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fluoride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aluminium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bisphosphonates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Phosphate deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Decreased intake",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Antacids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Impaired renal reabsorption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Primary defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            X-linked hypophosphatemic rickets (vitamin D resistant rickets, VDRR)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Hereditary hypophosphatemic rickets with hypercalciuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Sporadic acquired hypophosphatemic rickets",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Fanconi syndrome, Wilson disease, cystinosis, multiple myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Secondary defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Secondary hyperparathyroidism (renal tubular acidosis, type 1 and disorders of vitamin D metabolism)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Oncogenic osteomalacia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22589=[""].join("\n");
var outline_f22_3_22589=null;
var title_f22_3_22590="FCR for CLL";
var content_f22_3_22590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fludarabine, cyclophosphamide, and rituximab (FCR) for chronic lymphocytic leukemia",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rituximab",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        <p>",
"         Cycle 1: 375 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         IV",
"        </p>",
"        Cycles 2 to 6: 375 to 500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 0.9 percent sodium chloride (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated. Subsequent infusions: start at 100 mg/hour and escalate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated.",
"       </td>",
"       <td>",
"        All cycles: Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fludarabine",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 100 mL NS or D5W and administer over 30 minutes.",
"       </td>",
"       <td>",
"        <p>",
"         Cycle 1: Days 2 to 4",
"        </p>",
"        Cycles 2 to 6: Days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        250 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS or D5W and administer over 30 to 60 minutes",
"        <sup>",
"         &Delta;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        <p>",
"         Cycle 1: Days 2 to 4",
"        </p>",
"        Cycles 2 to 6: Days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 90 percent frequency of emesis). Prophylaxis is indicated on the days that cyclophosphamide is given. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cyclophosphamide is classified as an irritant, and not a true vesicant. Refer to UpToDate topic on \"Chemotherapy extravasation injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for tumor lysis syndrome:",
"        </strong>",
"        Due to the significant risk of tumor lysis syndrome during the first cycle, all patients should be well hydrated prior to and during therapy and receive allopurinol 300 mg orally once daily beginning the day prior to the first dose of rituximab and continuing for 14 days",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Tumor lysis syndrome: Prevention and treatment\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        The rate of severe (grade 3/4) infection was 25 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        . As such, we suggest prophylactic hematopoietic growth factors. In addition, due to the risk of developing Pneumocystis jiroveci pneumonia and other opportunistic infections, consider the use of antimicrobial, antifungal, and antiviral prophylaxis. Refer to UpToDate topics on \"Overview of infectious complications following purine analog therapy\" and \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Adjustment of initial cyclophosphamide and fludarabine may be required for renal dysfunction",
"        <sup>",
"         [4-7]",
"        </sup>",
"        . In addition, dose adjustments of cyclophosphamide may be needed for liver dysfunction. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatitis screening:",
"        </strong>",
"        Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for prophylaxis. Refer to UpToDate topic on&nbsp;\"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment and as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess renal and hepatic function prior to each cycle and as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess serum creatinine, potassium, phosphate, calcium, uric acid, and LDH daily during treatment for patients at risk for tumor lysis syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelosuppression:",
"        </strong>",
"        Treatment should be delayed until ANC greater than 1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 80,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If blood counts do not recover to ANC &gt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &gt;80,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        within five weeks from the last course of therapy, the daily dose of fludarabine should be reduced to 20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the daily dose of cyclophosphamide should be reduced to 200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for subsequent cycles. During these subsequent cycles, if blood counts do not recover to ANC &gt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &gt;80,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        within five weeks from the last course of therapy, the daily dose of fludarabine should be reduced to 15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the daily dose of cyclophosphamide should be reduced to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for any remaining cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; LD: lactate dehydrogenase; ANC: absolute neutrophil count.",
"     <br/>",
"     * Although initial studies of the FCR regimen utilized higher doses (500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) of rituximab in cycles 2 to 6, there have been no prospective studies that indicate that this increased dose is necessary. Some clinicians use the standard dose of rituximab (375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) for all six cycles of FCR.",
"     <br/>",
"     &Delta; The volume and rate of administration varies between institutions.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Hallek M, et al. Lancet 2010; 376:1164.",
"      </li>",
"      <li>",
"       Rituxan (rituximab) for injection. US FDA-approved product information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed February 1, 2012).",
"      </li>",
"      <li>",
"       Keating MJ, et al. J Clin Oncol 2005; 23:4079.",
"      </li>",
"      <li>",
"       Wierda W et al. J Clin Oncol 2005; 23:4070.",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at: www.dailymed.nlm.nih.gov, accessed on 2/1/2012).",
"      </li>",
"      <li>",
"       Cooper K, Bennett WM. Nephrotoxicity of common drugs used in clinical practice. Arch Intern Med 1987; 147:1213.",
"      </li>",
"      <li>",
"       Fludara (fludarabine) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed 2/1/2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22590=[""].join("\n");
var outline_f22_3_22590=null;
var title_f22_3_22591="Mogan clamp";
var content_f22_3_22591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mogan clamp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_3_22591=[""].join("\n");
var outline_f22_3_22591=null;
